[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2310
1. Chandrasoma P: The price of doubt is esophageal adenocarcinoma. Ann Surg; 2008 Mar;247(3):558-9; author reply 559-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The price of doubt is esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg. 2007 Jul;246(1):22-3 [17592285.001]
  • (PMID = 18376213.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


2. Barr H, Kendall C, Bazant-Hegemark F, Moayyedi P, Shetty G, Stone N: Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed; 2006;8(2):88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic screening and surveillance for Barrett's esophagus--clinical implications.
  • There is now a clear causal relationship between symptomatic gastroesophageal reflux and esophageal adenocarcinoma (Lagergren et al, 1999).
  • Screening a high-risk group such as men with gastroesophageal reflux disease (GERD) will result in the detection of more patients with Barrett's esophagus, many of whom are asymptomatic.
  • There are profound challenges with the accurate endoscopic and pathologic detection and categorization of Barrett's metaplasia, dysplasia , and, indeed, cancer.
  • New endoscopic detection methods are being investigated to improve the diagnosis and definition of the premalignant phenotype.
  • [MeSH-major] Barrett Esophagus / pathology. Esophagoscopy
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Humans. Population Surveillance

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gut. 2001 Dec;49(6):761-6 [11709508.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jan;16(1):41-50 [11856077.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):820-3 [11875016.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):274-9 [11943125.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1319-27 [12094844.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Gut. 2002 Sep;51(3):313-4 [12171948.001]
  • [Cites] Gut. 2002 Sep;51(3):314-5 [12171949.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gut. 2002 Nov;51(5):620-1 [12377793.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Gut. 2003 Jan;52(1):18-23 [12477753.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1758-66 [12806608.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):505-14 [14640762.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):112-27 [14653411.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Z Gastroenterol. 2004 Jun;42(6):499-504 [15190444.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gut. 1995 Jul;37(1):7-12 [7672684.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2291-3 [15571569.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2293-5 [15571570.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):561-74 [16185971.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • (PMID = 16926827.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  • [Other-IDs] NLM/ PMC1785170
  •  go-up   go-down


3. Alkhoury F, Martin JT, Fiedler P, Jaffe PE: Esophageal granular cell tumor colliding with intramucosal adenocarcinoma: a case report. Cases J; 2009;2:8093
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal granular cell tumor colliding with intramucosal adenocarcinoma: a case report.
  • We report a case of a granular cell tumor colliding with intramucosal adenocarcinoma of the esophagus.
  • A 58-year-old white was found to have a 5 mm nodule in the distal esophagus detected by upper gastrointestinal endoscopy performed as part of the workup of long standing reflux.
  • Endoscopic biopsies revealed intramucosal adenocarcinoma arising in the setting of Barrett's esophagus.
  • The adenocarcinoma infiltrated a granular cell tumor also present at the nodular site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fukuoka Igaku Zasshi. 1978 Dec 25;69(12):495-505 [738694.001]
  • [Cites] Dig Dis Sci. 2005 Oct;50(10):1875-9 [16187190.001]
  • [Cites] Am J Gastroenterol. 1985 Oct;80(10):758-62 [2994466.001]
  • [Cites] Cancer. 1970 Feb;25(2):415-22 [4312972.001]
  • [Cites] J Chir (Paris). 1981 May;118(5):325-9 [6265481.001]
  • [Cites] J Clin Gastroenterol. 1980 Dec;2(4):365-8 [6288795.001]
  • [Cites] J Surg Oncol. 1983 Oct;24(2):103-6 [6314047.001]
  • [Cites] Br J Radiol. 1995 Sep;68(813):1034-6 [7496688.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):896-901; discussion 902 [7574991.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):119-23 [7601022.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):268-72 [7630176.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):860-5 [8784020.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):543-7 [9158404.001]
  • [Cites] Otolaryngol Pol. 1995;49 Suppl 23:244-5 [9499911.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] Dig Dis Sci. 2001 Aug;46(8):1610-4 [11508657.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):262-4 [11869335.001]
  • [Cites] Dis Esophagus. 2002;15(1):88-92 [12060050.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Jan;38(1):97-101 [14676603.001]
  • [Cites] Fukuoka Igaku Zasshi. 1992 Jan;83(1):21-6 [1547986.001]
  • (PMID = 19830048.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740250
  •  go-up   go-down


Advertisement
4. Abdel-Latif MM, Kelleher D, Reynolds JV: Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res; 2009 May 1;153(1):172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target.
  • Esophageal adenocarcinoma is increasing in incidence and arises in a background of reflux induced inflammation, metaplasia, and dysplasia.
  • Because a role for NF-kappaB has been implicated in the pathogenesis of esophageal cancer, this transcription factor has been the focus of the current research of this devastating disease.
  • Research efforts to improve the effect of chemotherapy have led to an improvement in patient survival but there is still a need for improvement, and NF-kappaB is a potential target for cancer drug development.
  • In this review, we have attempted to highlight the possible role of NF-kappaB in esophageal adenocarcinoma and discuss the anticancer strategy with NF-kappaB as a promising molecular target in esophageal cancer therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. NF-kappa B / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533190.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / NF-kappa B
  • [Number-of-references] 58
  •  go-up   go-down


5. Yakoub D, Keun HC, Goldin R, Hanna GB: Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res; 2010 Nov 15;70(22):9129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients.
  • The variable rate of missed cancer in endoscopic biopsies and lack of other biomarkers reduce the effectiveness of surveillance programs in esophageal cancer.
  • Based on the "field cancerization" hypothesis that tumors arise within a transformed field with an altered biochemical phenotype, we sought to test if metabolic profiling could differentiate between histologically normal tissue from individuals with and without esophageal cancer.
  • Thirty-five patients with esophageal adenocarcinoma and 52 age-matched controls participated in the study.
  • Using 1H magic angle spinning-nuclear magnetic resonance spectroscopy of intact tissue, we generated metabolic profiles of tumor tissue, proximal histologically normal mucosa from cancer patients (PHINOM), and proximal histologically normal mucosa from a control group.
  • Using multivariate regression and receiver-operator characteristic analysis, we identified a panel of metabolites discriminating malignant and histologically normal tissues from cancer patients and from that of controls.
  • In particular, the PC/Glu ratio in histologically normal tissue signified the presence of esophageal cancer (n=123; area under the curve, 0.84; P<0.001).
  • In conclusion, our findings support the hypothesis of the presence of metabonomic field effects in esophageal cancer, even in non-Barrett's segments.
  • This indicates that metabolic profiling of tissue can potentially play a role in the surveillance of cancer by reporting on the phenotypic consequences of field cancerization.
  • [MeSH-major] Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Metabolome. Mucous Membrane / metabolism
  • [MeSH-minor] Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Cell Transformation, Neoplastic / metabolism. Diagnosis, Differential. Esophagus / metabolism. Esophagus / pathology. Female. Glutamic Acid / metabolism. Humans. Inosine / metabolism. Inositol / metabolism. Magnetic Resonance Spectroscopy. Male. Middle Aged. Multivariate Analysis. Phosphorylcholine / metabolism. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AACR.
  • (PMID = 20884633.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 107-73-3 / Phosphorylcholine; 3KX376GY7L / Glutamic Acid; 4L6452S749 / Inositol; 5A614L51CT / Inosine
  •  go-up   go-down


6. Liu G, Zhou W, Yeap BY, Su L, Wain JC, Poneros JM, Nishioka NS, Lynch TJ, Christiani DC: XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis; 2007 Jun;28(6):1254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
  • DNA damage is important in the pathogenesis of esophageal adenocarcinoma (EA).
  • [MeSH-major] Adenocarcinoma / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Xeroderma Pigmentosum Group D Protein / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264068.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA109193; United States / NCI NIH HHS / CA / CA110822; United States / NCI NIH HHS / CA / CA74386; United States / NCI NIH HHS / CA / ES/CA06409
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


7. Yong TY, Klebe S, Li JY: Acute critical leg ischemia: an uncommon initial manifestation of esophageal adenocarcinoma. J Palliat Med; 2009 Sep;12(9):841-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute critical leg ischemia: an uncommon initial manifestation of esophageal adenocarcinoma.
  • This report describes a patient who presented with acute critical right leg ischemia leading to the diagnosis of esophageal adenocarcinoma with widespread metastases.
  • However, he died 3 weeks after presentation due to progressive cancer.
  • [MeSH-major] Esophageal Neoplasms / complications. Ischemia / etiology. Leg / blood supply
  • [MeSH-minor] Acute Disease. Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Disease Progression. Fatal Outcome. Humans. Male. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719377.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M: Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene; 2005 Mar 3;24(10):1683-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.
  • Loss of p27 is associated with aggressive behavior in a variety of tumors, including Barrett's associated adenocarcinoma (BAA).
  • We have previously shown that gastroduodenal-esophageal reflux (GDER) together with N-methyl-N-benzylnitrosamine (MBN) induces Barrett's esophagus (BE) and malignant transformation of the esophageal mucosa in mice.
  • Similarly, flavopiridol reduced the prevalence of BAA (11 vs 32%, P=0.0098) and overall cancer prevalence (15 vs 60%, P<0.0001).
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Cell Cycle Proteins / physiology. Cell Transformation, Neoplastic. Esophageal Neoplasms / prevention & control. Flavonoids / pharmacology. Piperidines / pharmacology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adenocarcinoma / prevention & control. Animals. Barrett Esophagus / prevention & control. Carcinoma, Squamous Cell / prevention & control. Cyclin D1 / physiology. Cyclin-Dependent Kinase Inhibitor p27. Mice. Phosphorylation. Retinoblastoma Protein / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674336.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA89021; United States / NCI NIH HHS / CA / P20 CA90578; United States / NCI NIH HHS / CA / P50 CA90381; United States / NCI NIH HHS / CA / R01 CA90687
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cdkn1b protein, mouse; 0 / Cell Cycle Proteins; 0 / Flavonoids; 0 / Piperidines; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 45AD6X575G / alvocidib
  •  go-up   go-down


9. Ku GY, Ilson DH: Role of neoadjuvant therapy for esophageal adenocarcinoma. Surg Oncol Clin N Am; 2009 Jul;18(3):533-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of neoadjuvant therapy for esophageal adenocarcinoma.
  • This article examines the role of neoadjuvant therapy in the treatment of locally advanced esophageal adenocarcinoma.
  • Primary chemoradiotherapy is the accepted standard of care for medically inoperable patients, whereas adjuvant chemoradiotherapy may be considered for patients who undergo primary resection of lower esophageal/gastroesophageal junction tumors.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Neoadjuvant Therapy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500742.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 60
  •  go-up   go-down


10. Leers JM, DeMeester SR, Ayazi S, Tang AL, Peyre CG, Lipham JC, Hagen JA, DeMeester TR: Recurrence of intramucosal esophageal adenocarcinoma arising in a former esophagostomy site: a unique case report. Dis Esophagus; 2009;22(6):E17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intramucosal esophageal adenocarcinoma arising in a former esophagostomy site: a unique case report.
  • A 75-year-old male with a long history of gastroesophageal reflux symptoms developed adenocarcinoma proximally within a long segment of Barrett's esophagus.
  • Pathology showed an intramucosal adenocarcinoma, limited to the muscularis mucosa with surrounding high-grade dysplasia and intestinal metaplasia.
  • The proximal esophageal margin showed no tumor cells, but there was low-grade dysplasia within Barrett's esophagus.
  • Biopsy revealed an implant metastasis of esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021685.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Puntambekar SP, Agarwal GA, Joshi SN, Rayate NV, Sathe RM, Patil AM: Thoracolaparoscopy in the lateral position for esophageal cancer: the experience of a single institution with 112 consecutive patients. Surg Endosc; 2010 Oct;24(10):2407-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracolaparoscopy in the lateral position for esophageal cancer: the experience of a single institution with 112 consecutive patients.
  • METHODS: Patients with resectable thoracic or gastroesophageal junction cancer and medically fit for a three-stage esophagectomy underwent thoracoscopic esophagectomy in left lateral position.
  • Of these patients, 80 patients had middle-third esophageal cancer.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Laparoscopy / methods. Thoracoscopy / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Anastomosis, Surgical / methods. Carcinoma, Squamous Cell / surgery. Esophagus / surgery. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Postoperative Complications. Stomach / surgery. Video-Assisted Surgery

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Oct;25(10):3466-7 [21487858.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):372-8 [10703866.001]
  • [Cites] Ann Thorac Surg. 2003 Jan;75(1):217-22; discussion 222 [12537219.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):486-94; discussion 494-5 [14530720.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1113-5 [8553214.001]
  • [Cites] Surg Endosc. 2004 May;18(5):812-7 [15216864.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):367-70 [8472154.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Dec;112(6):1533-40; discussion 1540-1 [8975845.001]
  • [Cites] Am J Surg. 1995 May;169(5):471-5 [7747821.001]
  • [Cites] Ann Surg. 1981 Oct;194(4):438-46 [7283505.001]
  • [Cites] Surgery. 1997 Jul;122(1):8-14 [9225908.001]
  • [Cites] Surg Endosc. 1996 Feb;10(2):147-51 [8932617.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):374-80 [3335312.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):7-11 [1573620.001]
  • [Cites] J Am Coll Surg. 1995 Apr;180(4):461-4 [7719551.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1597-601 [16235125.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):176-82 [11285963.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):902-13 [14644277.001]
  • (PMID = 20204415.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Risques RA, Vaughan TL, Li X, Odze RD, Blount PL, Ayub K, Gallaher JL, Reid BJ, Rabinovitch PS: Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev; 2007 Dec;16(12):2649-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukocyte telomere length predicts cancer risk in Barrett's esophagus.
  • PURPOSE: Leukocyte telomere length has gained attention as a marker of oxidative damage and age-related diseases, including cancer.
  • We hypothesize that leukocyte telomere length might be able to predict future risk of cancer and examined this in a cohort of patients with Barrett's esophagus, who are at increased risk of esophageal adenocarcinoma and thus were enrolled in a long-term cancer surveillance program.
  • PATIENTS AND METHODS: In this prospective study, telomere length was measured by quantitative PCR in baseline blood samples in a cohort of 300 patients with Barrett's esophagus followed for a mean of 5.8 years.
  • Leukocyte telomere length hazard ratios (HR) for risk of esophageal adenocarcinoma were calculated using multivariate Cox models.
  • RESULTS: Shorter telomeres were associated with increased esophageal adenocarcinoma risk (age-adjusted HR between top and bottom quartiles of telomere length, 3.45; 95% confidence interval, 1.35-8.78; P = 0.009).
  • The relationship between telomere length and cancer risk was particularly strong among NSAID nonusers, ever smokers, and patients with low waist-to-hip ratio.
  • CONCLUSION: Leukocyte telomere length predicts risk of esophageal adenocarcinoma in patients with Barrett's esophagus independently of smoking, obesity, and NSAID use.
  • These results show the ability of leukocyte telomere length to predict the risk of future cancer and suggest that it might also have predictive value in other cancers arising in a setting of chronic inflammation.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Biomarkers, Tumor / analysis. Esophageal Neoplasms / pathology. Leukocytes / physiology. Telomere / metabolism


13. Voutilainen ME, Juhola MT: The changing epidemiology of esophageal cancer in Finland and the impact of the surveillance of Barrett's esophagus in detecting esophageal adenocarcinoma. Dis Esophagus; 2005;18(4):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing epidemiology of esophageal cancer in Finland and the impact of the surveillance of Barrett's esophagus in detecting esophageal adenocarcinoma.
  • We examined the epidemiology of esophageal cancer in Finland and the role of the surveillance of Barrett's esophagus (BE) in detecting esophageal adenocarcinoma (EA) in our own hospital referral area.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128777.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Bashash M, Shah A, Hislop G, Brooks-Wilson A, Le N, Bajdik C: Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999. Can J Gastroenterol; 2008 Feb;22(2):143-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999.
  • BACKGROUND: Geographical variation and temporal trends in the incidence of esophageal and gastric cancers vary according to both tumour morphology and organ subsite.
  • Both diseases are among the deadliest forms of cancer.
  • The incidence and survival rates for gastric and esophageal carcinoma in British Columbia (BC) between 1990 and 1999 are described.
  • METHODS: Incidence data for the period 1990 to 1999 were obtained from the BC Cancer Registry.
  • RESULTS: Between 1990 and 1999, 1741 esophageal cancer cases and 3431 gastric cancer cases were registered in BC.
  • There was an increase in the incidence of adenocarcinoma of the esophagus over time (EAPC=9.6%) among men, and of gastric cardia cancer among both women (EAPC=9.2%) and men (EAPC=3.8%).
  • Patients with proximal gastric (cardia) cancer had significantly better survival rates than patients with cancer in the lower one-third of the esophagus.
  • DISCUSSION: The incidences of proximal gastric cancer and esophageal adenocarcinoma are increasing, and their survival patterns are different.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] World J Surg. 2006 Oct;30(10):1864-9 [16983479.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):360-7; discussion 368-9 [11524589.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Am J Med. 2002 Oct 15;113(6):499-505 [12427500.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2070-6 [12775731.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] JAMA. 1988 Mar 18;259(11):1690-4 [3278148.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):41-55 [8850434.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56 [9752982.001]
  • [Cites] Surg Oncol. 1997 Dec;6(4):193-200 [9775405.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2271-8 [10070298.001]
  • [Cites] Cancer Invest. 2004;22(6):897-912 [15641488.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4131-9 [16015679.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Can J Gastroenterol. 2006 Apr;20(4):271-6 [16609756.001]
  • [Cites] Ann Thorac Surg. 2006 Sep;82(3):1073-7 [16928541.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):548-53 [11522738.001]
  • (PMID = 18299732.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2659133
  •  go-up   go-down


15. Wang RH: [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Sep;39(5):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia].
  • Barrett's esophagus is now clearly recognized as a preneoplasic condition.
  • Progression of metaplasia through dysplasia to adenocarcinoma is a widely accepted theory for esophageal carcinogenesis.
  • That high grade dysplasia is frequently found in association with esophageal adenocarcinoma.
  • Long-term endoscopic surveillance of high grade dysplasia in Barrett's esophagus facilitates detection and treatment of esophageal cancers in the early stage.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / therapy. Esophagoscopy
  • [MeSH-minor] Esophageal Neoplasms / diagnosis. Humans. Hyperplasia / pathology. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936731.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


16. Chiba N, Yoshioka T, Sakayori M, Mikami Y, Miyazaki S, Akiyama S, Otsuka K, Yamaura G, Shibata H, Kato S, Kato S, Ishioka C: AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report. Anticancer Res; 2005 Jul-Aug;25(4):2965-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report.
  • A case of alpha-fetoprotein (AFP)-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastases, responding to chemotherapy, is reported.
  • A 47-year-old man was admitted to our hospital with abdominal pain after subtotal esophagectomy for an esophageal adenocarcinoma in association with Barrett's esophagus, and was diagnosed as having multiple liver tumors.
  • Since microscopic examination of the resected tumor showed a poorly-differentiated adenocarcinoma with hepatoid features displaying AFP-immunoreactivity, the liver tumors were thus considered to be metastatic deposits.
  • This is the first report, to our knowledge, of effective chemotherapy for liver metastases from an AFP-producing hepatoid adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jul-Aug;26(4b):3203. Yoshiki, Mikami [corrected to Mikami, Yoshiki]
  • (PMID = 16080552.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Dim DC, Nugent SL, Peng HQ: Ganglioneuroma presenting as a paraesophageal mass lesion diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report. Acta Cytol; 2010 May-Jun;54(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration is a well-established modality in detection and diagnosis of mediastinal lesions.
  • Ganglioneuroma in a surgical specimen is a straightforward diagnosis; however, due to the infrequent occurrence of this entity, diagnosis by fine needle aspiration is more challenging.
  • A 75-year-old man with a history of adenocarcinoma of the lung was noted to have a mediastinal mass on chest computed tomography.
  • Upper endosonography identified a 40x17-mm mass extrinsic to the thoracic esophagus.
  • [MeSH-major] Ganglioneuroma / diagnosis. Mediastinal Neoplasms / pathology. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endosonography. Esophagus / pathology. Humans. Male. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518419.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


18. Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW: Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Gastrointest Endosc; 2010 Feb;71(2):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
  • BACKGROUND: Adenocarcinoma of the esophagus is frequently associated with Barrett's esophagus (BE).
  • The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported.
  • SETTING: A single National Cancer Institute Comprehensive Cancer Care Center experience.
  • PATIENTS: The study cohort consisted of 43 patients with stage I to IVA esophageal adenocarcinoma associated with BE who received either neoadjuvant or definitive chemoradiation therapy and underwent either esophagectomy or surveillance at our institution.
  • MAIN OUTCOME MEASUREMENT: The presence and extent of BE after chemoradiation therapy of esophageal adenocarcinoma associated with endoscopically documented pretreatment BE.
  • CONCLUSIONS: Chemoradiation therapy of esophageal adenocarcinoma does not eliminate tumor-associated BE, nor does it affect the length of the BE segment.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] C
  • (PMID = 20003971.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tokar JL, Haluszka O, Weinberg DS: Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol; 2007 Jan;17(1):10-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy of dysplasia and early-stage cancers of the esophagus.
  • Endoscopic treatments have become a viable alternative for some patients with early-stage esophageal neoplasia.
  • PDT has been reported to eradicate high-grade dysplasia (HGD) and early Barrett's cancers at rates ranging from 75% to 100% and 17% to 100%, respectively, and a recent randomized controlled trial confirmed that PDT may prevent progression of HGD to cancer.
  • In addition to PDT and EMR, several emerging endoscopic treatment options for superficial esophageal neoplasia may provide attractive alternatives to surgery.
  • [MeSH-major] Esophageal Neoplasms / therapy. Esophagoscopy. Precancerous Conditions / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Catheter Ablation. Esophagus / pathology. Humans. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185193.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 115
  •  go-up   go-down


20. Maqani N, Belkhiri A, Moskaluk C, Knuutila S, Dar AA, El-Rifai W: Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res; 2006 Jul;4(7):449-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA amplification at 17q is frequently detected in upper gastrointestinal adenocarcinomas (UGC; stomach and esophagus).
  • Adenocarcinomas of gastroesophageal junction and lower esophagus had the highest frequency of amplification (45%) compared with stomach tumors (27%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 17 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics


26. Anand O, Wani S, Sharma P: When and how to grade Barrett's columnar metaplasia: the Prague system. Best Pract Res Clin Gastroenterol; 2008;22(4):661-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's oesophagus (BO), a well-known precursor for oesophageal adenocarcinoma has been generating a great deal of controversy.
  • The initial step in diagnosing BO requires an accurate endoscopic recognition of the columnar lined oesophagus.
  • A reliable diagnosis of BO depends on its effective endoscopic recognition based on the key anatomic landmarks, followed by histological sampling of the columnar-lined epithelium.
  • Precise localisation of the gastrooesophageal junction is pivotal in the endoscopic diagnosis of BO.
  • Multiple ad-hoc grading systems and terminologies of BO have been proposed based on the Z-line appearance, presence or absence of intestinal metaplasia, and the length of Barrett's segment.
  • [MeSH-major] Barrett Esophagus / classification. Endoscopy, Gastrointestinal / methods. Esophagus / pathology. Intestinal Mucosa / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Metaplasia / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656823.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  •  go-up   go-down


27. Orlando RC: Pathogenesis of reflux esophagitis and Barrett's esophagus. Med Clin North Am; 2005 Mar;89(2):219-41, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of reflux esophagitis and Barrett's esophagus.
  • An understanding of the pathogenesis of reflux esophagitis and Barrett's esophagus requires knowledge of the noxious elements in gastric juice and the three major esophageal defenses designed to protect against them.
  • When the esophageal epithelium cannot prevent gastric acid from acidifying the intercellular spaces, the foundation is set for the development of the major symptoms, signs, and complications of reflux esophagitis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Barrett Esophagus / physiopathology. Esophageal Neoplasms / physiopathology. Esophagitis, Peptic / physiopathology. Gastroesophageal Reflux / physiopathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656926.001).
  • [ISSN] 0025-7125
  • [Journal-full-title] The Medical clinics of North America
  • [ISO-abbreviation] Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


28. Reddymasu SC, Sharma P: Advances in endoscopic imaging of the esophagus. Gastroenterol Clin North Am; 2008 Dec;37(4):763-74, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in endoscopic imaging of the esophagus.
  • The introduction of flexible fiberoptic endoscopy in the 1960s was a major step forward in the diagnosis and management of various esophageal disorders.
  • Magnification and high-resolution endoscopy, chromoendoscopy, narrow-band imaging, autofluorescence imaging, and confocal laser endomicroscopy are some of the recent advances that have shown promise in the diagnosis of squamous cell carcinoma, gastroesophageal reflux disease, Barrett's esophagus, and adenocarcinoma of the esophagus.
  • The purpose of this review is to summarize the recent advances in endoscopic imaging of the esophagus and their practical application for the gastroenterologist.
  • [MeSH-major] Endoscopy / methods. Esophagus / pathology
  • [MeSH-minor] Esophageal Diseases / diagnosis. Humans

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028316.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


29. Mebed AH: Aggressive surgical therapy for locally invasive differentiated thyroid carcinoma : an experience of nineteen ( 19 ) cases. J Egypt Natl Canc Inst; 2007 Dec;19(4):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It is well recognized that the optimum resection of locally advanced differentiated thyroid cancer invading adjacent vital neck structures is still controversial.
  • PATIENTS AND METHODS: This is a prospective study, carried in the National Cancer Institute, Cairo University, between January 2002 and January 2008 on 19 patients with primary differentiated thyroid carcinoma extending extrathyroid and invading surrounding neck structures.
  • RESULTS: The median age at diagnosis was 54 years.
  • Key Words : Differentiated thyroid cancer - Deltopectoral flap - Shave procedures - Extended surgery.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Adult. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Esophagus / pathology. Esophagus / surgery. Female. Humans. Larynx / pathology. Larynx / surgery. Male. Middle Aged. Neck Dissection. Neoplasm Invasiveness. Pharynx / pathology. Pharynx / surgery. Postoperative Complications. Skin / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652671.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


30. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol; 2008 Mar 01;26(7):1086-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
  • PURPOSE: The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although primary radiation therapy with concurrent chemotherapy produces similar results.
  • To this end, we compared survival, response, and patterns of failure of trimodality therapy to esophagectomy alone in patients with nonmetastatic esophageal cancer.
  • CONCLUSION: The results from this trial reflect a long-term survival advantage with the use of chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support trimodality therapy as a standard of care for patients with this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy. Esophagectomy
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Nov 1;26(31):5133-4; author reply 5134 [18838699.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1118-23 [8501498.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Surgery. 2005 Feb;137(2):172-7 [15674197.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Thorac Surg. 2007 Apr;83(4):1257-64 [17383322.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):156-63 [8558191.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):633-42 [1429085.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18309943.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037447
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Yuan SH, Yu JM, Yu YH, Fu Z, Guo HB, Liu TH, Yang XH, Yang GR, Li WW: [FDG PET/CT versus PET alone for pre-surgical detection of lymph node metastasis in esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FDG PET/CT versus PET alone for pre-surgical detection of lymph node metastasis in esophageal carcinoma].
  • OBJECTIVE: To compare the combined FDG PET/CT with PET alone in the detection of lymph node metastasis (LNM) for esophageal carcinoma patient.
  • METHODS: From November 2003 to August 2005, 35 patients with esophageal carcinoma underwent FDG PET/CT before esophagectomy and lymph node (LN) dissection.
  • Of these 35 patients, 3 had lesion at the upper third thoracic esophagus, 22 at the middle third and 10 at the lower third.
  • The true positive and true negative LNM interpretation reached 61 and 229 LN groups on PET/CT versus 53 and 217 LN groups on PET alone.
  • False negative LNM interpretation was found in 12 LN groups on PET alone, and 8 of them were corrected by PET/CT including one cervical LN, 4 paraesophageal LNs, one left gastric arterial LN, one left gastric cardia LN, one lesser gastric curve LN.
  • False positive interpretations on PET alone were found in 31 LN groups, 12 of them were corrected by PET/CT which included 9 false-positive interpretations due to physical tracer uptake (2 in the cervical region and 7 in gastrointestinal tract ) and 3 lesions with heterogeneous tracer uptake in the primary tumor.
  • CONCLUSION: Compared with FDG PET alone, FDG PET combined with CT can improve the sensitivity and accuracy in detection of lymph node metastasis in esophageal carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Lymphatic Metastasis / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Esophagectomy. Female. Fluorodeoxyglucose F18. Humans. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Lymph Nodes / surgery. Male. Middle Aged. Neck Dissection. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649642.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Cooper SC, Croft S, Day R, Thomson CS, Trudgill NJ: The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev; 2010 May;19(3):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of oesophageal cancer is not affected by a diagnosis of breast cancer.
  • Oesophageal adenocarcinoma (OAC) is less common and develops at a later age in women compared with men.
  • A cohort of women with breast cancer, a tumour commonly treated with oestrogen antagonists, was examined to identify the subsequent risk of developing OAC.
  • Earlier studies have implicated radiotherapy in increasing oesophageal cancer (OC) risk among women with breast cancer.
  • West Midlands Cancer Intelligence Unit data recording cancer diagnosis and treatment information was examined to identify patients with a first malignant primary breast cancer during 1977-2004.
  • Patients were followed until diagnosis of a second primary cancer, death or end of the time period examined.
  • No difference was identified when examined by OC morphology.There was no association between breast cancer and a second primary OC.
  • Radiotherapy that avoids deep irradiation in the treatment of breast cancer, local nodes or recurrence was not associated with an increased risk of developing a second primary OC.
  • [MeSH-major] Breast Neoplasms / complications. Esophageal Neoplasms / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145541.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


33. Heffernan E, Fennelly D, Collins CD: Multiple metastases to skeletal muscle from carcinoma of the esophagus detected by FDG PET-CT imaging. Clin Nucl Med; 2006 Dec;31(12):810-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple metastases to skeletal muscle from carcinoma of the esophagus detected by FDG PET-CT imaging.
  • A 67-year-old woman was treated with neoadjuvant chemotherapy, esophagectomy, and subsequent radiotherapy for T3N1 poorly differentiated adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Esophageal Neoplasms / diagnosis. Fluorodeoxyglucose F18. Muscle Neoplasms / diagnosis. Muscle Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117081.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Bosetti C, Gallus S, Garavello W, La Vecchia C: Smoking cessation and the risk of oesophageal cancer: An overview of published studies. Oral Oncol; 2006 Nov;42(10):957-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking cessation and the risk of oesophageal cancer: An overview of published studies.
  • The epidemiologic studies on oesophageal cancer and smoking cessation published before December 2005 were reviewed here.
  • The results from at least 10 cohort and 10 case-control studies indicated that former smokers had a lower risk of squamous-cell or unspecified oesophageal cancer than current smokers.
  • Most investigations showed that the risk of oesophageal cancer remains elevated many years (at least 10) after cessation of smoking, to decline by about 40% only thereafter.
  • A few studies investigated the effect of smoking cessation on adenocarcinoma, and did not report a clear reduction of risk.
  • Data on oesophageal adenocarcinoma are however too limited to provide adequate inference on the relation with time since smoking cessation.
  • In conclusion, cessation of smoking could have an appreciable impact in reducing (squamous-cell) oesophageal cancer, and represents an obvious priority for prevention and public-health purposes.
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Smoking / adverse effects. Smoking Cessation
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Case-Control Studies. Cohort Studies. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919996.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686859
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


35. Li Y, Woodall C, Wo JM, Zheng H, Ng CK, Ray MB, Martin RC: The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma. Cancer Invest; 2008 Apr-May;26(3):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma.
  • BACKGROUND: In this study, we investigate the use of PET scanning in the carcinogenic progression of reflux esophagitis to Barrett's esophagus to high grade dysplasia to esophageal adenocarcinoma, and correlate the uptake levels of 18F-FDG related to histological changes, and the rates of proliferation and apoptosis.
  • The higher level of 18F-FDG uptake within esophageal epithelium was identified in intestinal metaplastic transformation and esophagoduodenal adenocarcinoma by histological examination.
  • CONCLUSIONS: Dynamic PET scanning represents a powerful tool in analyzing morphological carcinogenic transformation non-invasively in the esophagus.
  • 18F- FDG accumulation was a sensitive marker in reflux esophageal injury carcinogenic progression from intestinal metaplasia to EAC.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / pathology. Positron-Emission Tomography. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317969.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


36. Soma T, Kaganoi J, Kawabe A, Kondo K, Tsunoda S, Imamura M, Shimada Y: Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer; 2006 Aug 15;119(4):771-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer.
  • Bile acids are known to promote the growth of gastrointestinal cancer.
  • In vitro, esophageal squamous cell carcinoma (ESCC) cells and esophageal adenocarcinoma cells were studied.
  • Our results suggest that bile acids, important constituents of duodenal fluid, stimulate the development of human esophageal cancer by promoting angiogenesis via the COX-2 pathway.
  • [MeSH-major] Chenodeoxycholic Acid / pharmacology. Esophageal Neoplasms / blood supply. Esophageal Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16557574.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 0GEI24LG0J / Chenodeoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


37. Marinella MA, Baumann M: Cullen's sign associated with metastatic esophageal carcinoma. J Hosp Med; 2008 May;3(3):277-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cullen's sign associated with metastatic esophageal carcinoma.
  • We report the case of a patient with metastatic adenocarcinoma of the esophagus who developed Cullen's sign shortly before death.
  • [MeSH-major] Adenocarcinoma / complications. Ecchymosis / etiology. Esophageal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Society of Hospital Medicine
  • (PMID = 18571807.001).
  • [ISSN] 1553-5606
  • [Journal-full-title] Journal of hospital medicine
  • [ISO-abbreviation] J Hosp Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. van Heijl M, Sprangers MA, de Boer AG, Lagarde SM, Reitsma HB, Busch OR, Tilanus HW, van Lanschot JJ, van Berge Henegouwen MI: Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol; 2010 Jan;17(1):23-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer.
  • BACKGROUND: In patients with esophageal cancer, evidence for prognostic significance of preoperative quality of life (QoL) is limited, while the prognostic significance of postoperative QoL has not been investigated at all.
  • AIM: To determine whether preoperative and postoperative QoL measurements can predict survival independently from clinical and pathological factors, in patients with potentially curable esophageal adenocarcinoma.
  • CONCLUSION: In the present paper the first large consecutive series of potentially curable esophageal cancer patients is presented in whom prospectively collected QoL data before and after potentially curative surgical resection were used to predict survival.
  • Both preoperative (physical symptoms) and postoperative (social functioning, pain, and activity level) QoL subscales are independent predictors of survival in potentially curable patients with esophageal adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Quality of Life

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Dec;87(12):1716-21 [11122191.001]
  • [Cites] Biometrics. 2001 Mar;57(1):114-9 [11252585.001]
  • [Cites] Gut. 2001 Aug;49(2):227-30 [11454799.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1351-7 [12091066.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1367-72 [14598416.001]
  • [Cites] Qual Life Res. 2004 Mar;13(2):311-20 [15085903.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Med Care. 1988 Jul;26(7):724-35 [3393032.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1034-8 [2257209.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1833-8 [1453197.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1005-53 [15939716.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6865-72 [16192578.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Qual Life Res. 2006 Oct;15(8):1297-306 [16830258.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Ann Thorac Surg. 2007 Apr;83(4):1257-64 [17383322.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1361-8 [17582230.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):888-93 [18268490.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1355-63 [18227528.001]
  • [Cites] Endoscopy. 2008 Jun;40(6):464-71 [18543134.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3289-98 [18670823.001]
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):12-3 [19851809.001]
  • (PMID = 19830496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2805800
  •  go-up   go-down


39. Shaheen NJ, Peery AF, Overholt BF, Lightdale CJ, Chak A, Wang KK, Hawes RH, Fleischer DE, Goldblum JR, AIM Dysplasia Investigators: Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc; 2010 Sep;72(3):490-496.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus.
  • BACKGROUND: After endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Catheter Ablation / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagoscopy. Postoperative Complications / pathology. Postoperative Complications / surgery. Precancerous Conditions / pathology. Precancerous Conditions / surgery
  • [MeSH-minor] Aged. Biopsy. Disease Progression. Esophagus / pathology. Female. Follow-Up Studies. Humans. Male. Metaplasia. Middle Aged. Predictive Value of Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):239-45 [9500226.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Endoscopy. 2008 May;40(5):380-7 [18459074.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):867-76 [18561930.001]
  • [Cites] Endoscopy. 2008 Dec;40(12):1008-15 [19065484.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1366-73 [19491850.001]
  • (PMID = 20598302.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00282672
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007634-15; United States / NIDDK NIH HHS / DK / T32 DK 07634; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / IH P30 DK034987; United States / NIDDK NIH HHS / DK / T32 DK007634
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS289916; NLM/ PMC3093936
  • [Investigator] Shaheen NJ; Madanick RD; Galanko JA; Sharma P; Overholt BF; Wolfsen HC; Sampliner RE; Wang KK; Falk GW; Bronner MP; Goldblum JR; Bennett AE; Jobe BA; Eisen GM; Fennerty MB; Hunter JG; Fleischer DE; Sharma VK; Hawes RH; Hoffman BJ; Rothstein RI; Gordon SR; Mashimo H; Chang KJ; Muthusamy VR; Edmundowicz SA; Spechler SJ; Siddiqui AA; Souza RF; Infantolino A; Kimmey MB; Chak A; Lightdale CJ
  •  go-up   go-down


40. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • While type I tumors benefit from a transthoracic en bloc esophagectomy including a two-field LAD, type II and III tumors can be treated by an extended total gastrectomy with a transhiatal resection of the distal esophagus and LAD of the lower mediastinum and the abdominal D2 compartment.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


41. Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, Walther B: Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg; 2008 Jun;32(6):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.
  • BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy.
  • CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery


42. Corley DA, Kubo A, Levin TR, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Block G: Iron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study. Am J Gastroenterol; 2008 Dec;103(12):2997-3004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study.
  • OBJECTIVE: High iron stores are a proposed modifiable risk factor for esophageal adenocarcinoma, but minimal human data exist.
  • We evaluated whether iron intake and iron stores were associated with Barrett's esophagus, a metaplastic change that is a strong risk factor for esophageal adenocarcinoma.
  • We identified all persons with a new diagnosis of Barrett's esophagus (cases); they were matched to persons with GERD (without Barrett's esophagus) and to population controls.
  • Compared with population controls, Barrett's esophagus patients had lower dietary iron intakes (4th vs 1st quartiles, odds ratio [OR]= 0.37, 95% confidence interval [CI] 0.17-0.80), similar total iron intakes (including supplement use), and lower iron stores (4th vs 1st quartiles, ferritin OR = 0.24, 95% CI 0.14-0.40;% transferrin saturation OR = 0.66, 95% CI 0.41-1.04; P value trend <0.01 and 0.03, respectively).
  • CONCLUSIONS: Patients with Barrett's esophagus had lower dietary iron intakes and lower serum iron stores than controls in our population.
  • These findings do not provide support for the current hypothesis that high iron stores or a high iron intake are risk factors for Barrett's esophagus, a potential early event in the carcinogenic sequence for esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Am J Clin Nutr. 2001 Mar;73(3):638-46 [11237943.001]
  • [Cites] Hepatology. 2001 Mar;33(3):647-51 [11230745.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1119-29 [11470739.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Acta Haematol. 2002;107(3):145-9 [11978935.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Int J Food Sci Nutr. 2003 Nov;54(6):485-90 [14522694.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:40-61 [14633776.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Natl Cancer Inst. 1986 Apr;76(4):605-10 [3007843.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Am J Clin Nutr. 1989 Nov;50(5 Suppl):1133-8; discussion 1231-5 [2683721.001]
  • [Cites] Hepatology. 1990 Apr;11(4):566-9 [2158479.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Dig Dis Sci. 1991 Apr;36(4):405-8 [2007356.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Med Clin North Am. 1992 May;76(3):549-66 [1578956.001]
  • [Cites] J Am Diet Assoc. 1992 Jun;92(6):686-93 [1607564.001]
  • [Cites] J Clin Gastroenterol. 1992 Jun;14(4):288-92 [1607604.001]
  • [Cites] Ann Intern Med. 1993 Feb 1;118(3):201-10 [8417638.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):160-2 [7829208.001]
  • [Cites] Ann Nutr Metab. 1994;38(4):192-202 [7832579.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21167-76 [8702887.001]
  • [Cites] Nutr Cancer. 1997;27(3):298-309 [9101561.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1021-8 [9305701.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Med Care. 2005 Jan;43(1):34-43 [15626932.001]
  • [Cites] Blood. 2005 Jul 15;106(2):740-5 [15790781.001]
  • [Cites] J Nutr. 2005 Aug;135(8):1974-80 [16046725.001]
  • [Cites] Alcohol. 2005 Apr;35(3):243-9 [16054986.001]
  • [Cites] Health Serv Res. 2001 Dec;36(6 Pt 2):180-93 [16148968.001]
  • [Cites] Genet Test. 2005 Fall;9(3):231-41 [16225403.001]
  • [Cites] Am J Clin Nutr. 2005 Nov;82(5):1024-31 [16280434.001]
  • [Cites] J Am Coll Nutr. 2006 Feb;25(1):64-9 [16522934.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3147-52 [16425287.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1531-6 [10910955.001]
  • (PMID = 18853987.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK63616; United States / NIDDK NIH HHS / DK / DK063616-05; United States / NIDDK NIH HHS / DK / K08 DK02697; United States / NIDDK NIH HHS / DK / K08 DK002697; United States / NIDDK NIH HHS / DK / R01 DK063616; United States / NIDDK NIH HHS / DK / DK063616-06A1; United States / NIDDK NIH HHS / DK / R01 DK063616-05; United States / NIDDK NIH HHS / DK / R01 DK063616-06A1; United States / NIDDK NIH HHS / DK / DK002697-05; United States / NIDDK NIH HHS / DK / K08 DK002697-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iron, Dietary; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ NIHMS99905; NLM/ PMC2671068
  •  go-up   go-down


43. Ibiebele TI, Hughes MC, O'Rourke P, Webb PM, Whiteman DC, Australian Cancer Study: Cancers of the esophagus and carbonated beverage consumption: a population-based case-control study. Cancer Causes Control; 2008 Aug;19(6):577-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancers of the esophagus and carbonated beverage consumption: a population-based case-control study.
  • OBJECTIVE: Increased consumption of carbonated soft drinks has been hypothesized to be a risk factor for esophageal adenocarcinoma (EAC); however, previous studies have not found supportive evidence.
  • We analyzed data from a population-based case-control study to measure the association between carbonated beverage intake and risk of adenocarcinomas and squamous cell carcinoma (SCC) of the esophagus.
  • METHODS: A food frequency questionnaire (FFQ) was used to collect data on carbonated soft drink and beer consumption; a self-administered questionnaire was used to collect information on demographic, socioeconomic, and lifestyle-related factors from 1,484 control subjects, 294 cases with EAC, 325 cases with adenocarcinoma of the esophagogastric junction (EGJAC), and 238 cases with SCC of the esophagus.
  • RESULTS: High intake of soft drinks was not associated with risk of EAC (fully adjusted OR = 0.94, 95% CI 0.53-1.66, p for trend = 0.85) or EGJAC (fully adjusted OR = 1.07, 95% CI 0.67-1.73, p for trend = 0.89) but was inversely associated with SCC of the esophagus (fully adjusted model OR = 0.40, 95% CI 0.20-0.78, p for trend = 0.04).
  • High intake of beer was inversely associated with risk of EGJAC (fully adjusted OR = 0.53, 95% CI 0.35-0.81) but positively associated with esophageal SCC (fully adjusted model OR = 1.86, 95% CI 1.17-2.95).
  • CONCLUSION: High levels of consumption of carbonated soft drinks do not appear to increase the risk of either adenocarcinomas or SCC of the esophagus.
  • [MeSH-major] Beer / adverse effects. Carbonated Beverages / adverse effects. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology
  • [MeSH-minor] Adenocarcinoma / etiology. Adult. Case-Control Studies. Esophagogastric Junction / pathology. Female. Humans. Male. Middle Aged. Nutrition Surveys. Odds Ratio

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231869.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Investigator] Whiteman DC; Webb PM; Green AC; Hayward NK; Parsons PG; Purdie DM; Smithers BM; Gotley D; Clouston A; Brown I; Moore S; Harrap K; Sadkowsky T; O'Brien S; Minehan E; Roffe D; O'Keefe S; Lipshut S; Connor G; Berry H; Walker F; Barnes T; Thomas J; Terry L; Connard M; Bowes L; Malt M; White J
  •  go-up   go-down


44. Abrams JA, Fields S, Lightdale CJ, Neugut AI: Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol; 2008 Jan;6(1):30-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy.
  • BACKGROUND & AIMS: The incidence of esophageal adenocarcinoma (EAC) in blacks and Hispanics is well-described, but racial differences in the risk of Barrett's esophagus (BE) have not been directly studied.
  • These differences in prevalence are comparable to the relative incidence rates observed with EAC, implying that progression from BE to adenocarcinoma does not vary by race/ethnicity.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10):1005-10 [16268976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2467-71 [16284364.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1050-61 [16221805.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • [Cites] Neurology. 2001 Jan 9;56(1):49-56 [11148235.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1692-9 [15188164.001]
  • [Cites] J Clin Epidemiol. 2004 Jun;57(6):580-9 [15246126.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1657-66 [15330898.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1067-75 [15480985.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Gastroenterology. 1992 Sep;103(3):813-6 [1499931.001]
  • [Cites] Am J Epidemiol. 1995 Jun 1;141(11):1038-46 [7771440.001]
  • [Cites] Dig Dis Sci. 1998 May;43(5):1038-41 [9590419.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • (PMID = 18063419.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K05 CA089155; United States / NCI NIH HHS / CA / R25 CA094061
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS475353; NLM/ PMC3712273
  •  go-up   go-down


45. Bando H, Ikematsu H, Fu KI, Oono Y, Kojima T, Minashi K, Yano T, Matsuda T, Saito Y, Kaneko K, Ohtsu A: A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection. World J Gastroenterol; 2010 Jan 21;16(3):392-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we describe an early colonic carcinoma which developed in a colonic interposition 14 years after surgery for esophageal cancer, which was successfully treated by endoscopic submucosal dissection (ESD).
  • An 80-year-old man underwent colonic interposition between the upper esophagus and stomach after surgery for an early esophageal squamous cell carcinoma in 1994.
  • An endoscopic biopsy revealed moderately differentiated adenocarcinoma histologically, however, we diagnosed the lesion as an intramucosal carcinoma based on the endoscopic findings.
  • Histologically, the lesion was an intramucosal moderately differentiated adenocarcinoma in a tubular adenoma.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Endoscopy, Gastrointestinal

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2):278-83 [18951131.001]
  • [Cites] Endoscopy. 1981 May;13(3):134 [7238429.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2304-7 [3440237.001]
  • [Cites] Gut. 1989 Jun;30(6):880-1 [2753412.001]
  • [Cites] Aust N Z J Surg. 1992 Feb;62(2):158-60 [1586307.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):80-3 [8133180.001]
  • [Cites] Gastrointest Endosc. 1994 Jul-Aug;40(4):485-9 [7926542.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):797-9 [8847026.001]
  • [Cites] Am J Gastroenterol. 1997 Dec;92(12):2303-4 [9399777.001]
  • [Cites] J Clin Gastroenterol. 2006 Sep;40(8):765-6 [16940896.001]
  • [Cites] Endoscopy. 2006;38 Suppl 2:E95 [17366431.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):966-73 [17524403.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):284-90 [18389446.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):830-9 [18155216.001]
  • [Cites] Ann Surg. 1968 Jan;167(1):98-100 [5635190.001]
  • (PMID = 20082488.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 16
  • [Other-IDs] NLM/ PMC2807963
  •  go-up   go-down


46. Gross SA, Wolfsen HC: The role of photodynamic therapy in the esophagus. Gastrointest Endosc Clin N Am; 2010 Jan;20(1):35-53, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of photodynamic therapy in the esophagus.
  • Porfimer sodium PDT has been used extensively with proven long-term efficacy and durability for the ablation of Barrett esophagus and high-grade dysplasia. and early esophageal adenocarcinoma.
  • Future use of PDT in esophageal disease depends on the development of improved dosimetry and patient selection to optimize treatment outcomes, while minimizing adverse events and complications.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951793.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid; 97067-70-4 / Dihematoporphyrin Ether; FU21S769PF / temoporfin
  • [Number-of-references] 108
  •  go-up   go-down


47. Weimann A, Rieger A, Zimmermann M, Gross M, Hoffmann P, Slevogt H, Morawietz L: Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus. Virchows Arch; 2010 Nov;457(5):537-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
  • In esophageal neoplasms, the histopathologic differentiation between Barrett's esophagus with or without intraepithelial neoplasia and adenocarcinoma is often challenging.
  • The expression of CDX2, LI-cadherin, mucin 2 (MUC2), blood group 8 (BG8, Lewis(y)), claudin-2, and villin was investigated in normal gastroesophageal (n = 23) and in Barrett's (n = 17) mucosa, in low-grade (n = 12) and high-grade (n = 9) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry.
  • For CDX2 and LI-cadherin, the immunoreactivity score was highest in IEN while for MUC2, BG8, and villin, it dropped gradually from Barrett's via IEN to adenocarcinoma, and expression of Claudin-2 was only weak and focal in all lesions.
  • MUC2 and LI-cadherin are useful immunohistochemical markers for the differentiation between normal glandular mucosa, Barrett's mucosa, IEN, and invasive carcinoma of the esophagus; however, none of the examined markers was helpful for the differentiation between low-grade and high-grade IEN.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1565-77 [12404231.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1353-69 [8207063.001]
  • [Cites] Exp Cell Res. 2009 Jun 10;315 (10 ):1779-89 [19371634.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):316-24 [12692197.001]
  • [Cites] J Cell Biol. 1987 Jul;105(1):359-69 [2440895.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):562-8 [15178443.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Cancer Sci. 2003 May;94(5):425-30 [12824888.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1442-7 [14576477.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):663-71 [9092948.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] J Cell Biol. 1999 Nov 15;147(4):891-903 [10562289.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 24;300(4):813-8 [12559945.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):53-7 [2912874.001]
  • [Cites] J Gastroenterol. 2003;38(1):14-22 [12560917.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 May;46(2):187-206 [12711361.001]
  • [Cites] Protein Eng. 1996 May;9(5):447-59 [8795045.001]
  • [Cites] Dis Esophagus. 2008;21(1):43-50 [18197938.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] J Gastroenterol. 2002;37(2):94-100 [11871772.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):357-9 [11331951.001]
  • [Cites] Int J Surg Pathol. 2010 Oct;18(5):330-7 [20444732.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):618-24 [14623315.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):740-6 [7833053.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Indian J Cancer. 2007 Jan-Mar;44(1):1-5 [17401217.001]
  • [Cites] Hum Pathol. 1992 May;23(5):475-6 [1568742.001]
  • [Cites] J Pathol. 2005 Apr;205(5):615-22 [15732140.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):961-8 [16133365.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):431-45 [15750830.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Biochem Cell Biol. 1998;76(6):957-69 [10392709.001]
  • [Cites] Med Electron Microsc. 2003 Sep;36(3):147-56 [14505058.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] J Histochem Cytochem. 2005 Jan;53(1):75-85 [15637340.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:136-43 [11193569.001]
  • (PMID = 20844891.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH17 protein, human; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / CLDN2 protein, human; 0 / Cadherins; 0 / Claudins; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Mucin-2; 0 / villin
  •  go-up   go-down


48. Lopes CV, Pereira-Lima JC, Hartmann AA, Tonelotto E, Salgado K: [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?]. Arq Gastroenterol; 2005 Oct-Dec;42(4):233-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] O critério de positividade para a análise imunoistoquímica da p53 na confirmação da displasia do esôfago de Barrett faz diferença?
  • BACKGROUND: Barrett's esophagus is the most serious complication of the gastroesophageal reflux disease and presents a malignant potential.
  • The expression of the tumoral marker p53 increases with the dysplasia-adenocarcinoma sequence.
  • AIMS: To evaluate the p53 expression in Barrett's esophagus with or without dysplasia according to the two positive immunostaining criteria.
  • MATERIALS AND METHODS: The material was constituted by endoscopic biopsy specimens from 42 patients with Barrett's esophagus.
  • The diagnosis of dysplasia was confirmed by the agreement between three pathologists.
  • CONCLUSIONS: In this group, p53 immunohistochemical expression, regardless of positive criteria take into account, was not useful for detecting dysplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / pathology. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444378.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


49. Wu G, Bybel B, Brunken R, Lin H, Neumann D: PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma. Clin Nucl Med; 2005 May;30(5):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma.
  • A 67-year-old man with progressive dysphagia was recently diagnosed with a gastroesophageal junction adenocarcinoma.
  • Needle biopsy was performed and confirmed metastatic esophageal adenocarcinoma.
  • A case of skeletal muscle metastases from late-stage (IV) gastroesophageal adenocarcinoma was previously reported.
  • The case supports the previous report that PET is superior in detecting distant metastases for initial staging of esophageal carcinoma over CT.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Muscle Neoplasms / radionuclide imaging. Muscle Neoplasms / secondary. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827406.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


50. Lenglinger J, Eisler M, Riegler FM: Adiposity and columnar-lined esophagus. Am J Gastroenterol; 2008 May;103(5):1316-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiposity and columnar-lined esophagus.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology. Gastroesophageal Reflux / epidemiology. Obesity / epidemiology
  • [MeSH-minor] Body Mass Index. Comorbidity. Esophagoscopy. Esophagus / pathology. Humans. Mucous Membrane / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2008 Feb;103(2):292-300 [17986313.001]
  • (PMID = 18477363.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


51. Odze RD: Update on the diagnosis and treatment of Barrett esophagus and related neoplastic precursor lesions. Arch Pathol Lab Med; 2008 Oct;132(10):1577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the diagnosis and treatment of Barrett esophagus and related neoplastic precursor lesions.
  • CONTEXT: At present, Barrett esophagus is the most common cause of esophageal adenocarcinoma.
  • In the past 20 years, the incidence of esophageal adenocarcinoma in white males has exceeded that of tumors of the colorectum, lung, prostate, and skin.
  • OBJECTIVES: To (1) provide an evidence-based review of the diagnosis, classification, and histologic differentiation of Barrett esophagus from gastric carditis, (2) provide a summary of the key pathologic features of precursor lesions, such as dysplasia, and (3) evaluate adjunctive markers of dysplasia and predictive markers for the development of cancer.
  • The natural history and risk of cancer in patients with Barrett esophagus is also reviewed.
  • CONCLUSIONS: The current definition of Barrett esophagus is partially flawed because not all cases are endoscopically recognizable, nongoblet epithelium is biologically intestinalized, and determination of the presence or absence of goblet cells is susceptible to sampling error.
  • Differentiation of ultrashort segment Barrett esophagus from chronic gastric carditis can be accomplished, in a minority of cases, by evaluating for the presence or absence of histologic features that are known to be associated with Barrett esophagus.
  • Dysplasia in Barrett esophagus begins in the crypt bases and then extends more superficially to include the upper portions of the crypts and surface epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2009 Dec;133(12):1909; author reply 1909-10 [19961240.001]
  • (PMID = 18834215.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


52. Pruyt M, Devriendt D, Vanneste A: Malignant melanoma and adenocarcinoma of a Barrett oesophagus. Acta Chir Belg; 2006 Sep-Oct;106(5):616-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and adenocarcinoma of a Barrett oesophagus.
  • An adenocarcinoma with a malignant melanoma in a Barrett oesophagus is extremely rare.
  • The diagnosis of a malignant melanoma can be difficult but can be made by tissue examination with a special immunoreaction with several markers to see it expresses S-100, but lacks activity for KER and EMA.
  • In our case it was obvious that there were two different tumours because the MM was negative for cytokeratin, but the adenocarcinoma was positive for cytokeratin.
  • [MeSH-major] Adenocarcinoma / complications. Barrett Esophagus / complications. Esophageal Neoplasms / complications. Melanoma / complications. Neoplasms, Multiple Primary / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168284.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


53. Saito H, Shuto K, Ota T, Toma T, Ohira G, Natsume T, Uesato M, Akutsu Y, Kono T, Matsubara H: [A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2406-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
  • He was diagnosed to have an advanced esophageal adenocarcinoma in the middle thoracic esophagus for which chemoradiation therapy was started.
  • Pathological finding was poorly-differentiated tubular adenocarcinoma.
  • Surgical resection may contribute to improving the prognosis of solitary adrenal metastasis of esophageal cancer without the other noncurative factors.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224588.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Lin L, Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG: Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer; 2006 Apr;45(4):319-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma.
  • Gene amplification is one of the mechanisms to activate oncogenes in many cancers, including esophageal adenocarcinoma (EA).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 3. Esophageal Neoplasms / genetics


55. Takubo K, Aida J, Sawabe M, Arai T, Kato H, Pech O, Arima M: The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract Res Clin Gastroenterol; 2008;22(4):569-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of primary oesophageal adenocarcinoma in Caucasian men has recently been increasing rapidly.
  • Therefore, primary oesophageal adenocarcinoma, columnar-lined oesophagus (CLO) or Barrett's oesophagus and the normal condition of the lower segment of the oesophagus are currently receiving worldwide attention in the medical field.
  • We review definitions of the OGJ, the pattern of the squamocolumnar junction (SCJ), oesophageal cardiac-type glands beneath the squamous epithelium, the normal squamous epithelium, columnar islands in squamous-lined mucosa, squamous islands in CLO and newly reported metaplastic changes in the OGJ zone.
  • [MeSH-minor] Biopsy. Esophageal Sphincter, Upper / cytology. Humans. Stomach / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656817.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


56. Mutoh H: [Expression of transcription factor in Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of transcription factor in Barrett's esophagus].
  • Barrett's esophagus is the result of chronic injury which is usually caused by gastroesophageal reflux.
  • Specialized columnar epithelium (SCE) is characteristic of Barrett's esophagus and has a malignant predisposition.
  • Adenocarcinoma in Barrett's esophagus is believed to develop through the metaplasia-dysplasia-carcinoma sequence.
  • P53, beta-catenin, PPARgamma, and estrogen receptor beta are closely related to the development of esophageal carcinogenesis.
  • [MeSH-major] Barrett Esophagus / genetics. Transcription Factors
  • [MeSH-minor] Adenocarcinoma / genetics. Cytoskeletal Proteins. Esophageal Neoplasms / genetics. Esophagus / pathology. Estrogen Receptor beta. Gastroesophageal Reflux / genetics. Genes, p53. Homeodomain Proteins. Humans. Metaplasia / genetics. NF-kappa B. PPAR gamma. Trans-Activators. beta Catenin

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101223.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Estrogen Receptor beta; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / PPAR gamma; 0 / Trans-Activators; 0 / Transcription Factors; 0 / beta Catenin
  • [Number-of-references] 29
  •  go-up   go-down


57. Razvi MH, Peng D, Dar AA, Powell SM, Frierson HF Jr, Moskaluk CA, Washington K, El-Rifai W: Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. Genes Chromosomes Cancer; 2007 Oct;46(10):914-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Transcription, Genetic
  • [MeSH-minor] Antigens, CD13 / genetics. Antigens, CD13 / metabolism. Esophageal Neoplasms / genetics. Esophageal Neoplasms / metabolism. Expressed Sequence Tags. Female. Gastric Mucosa / metabolism. Gene Library. Humans. Immunoenzyme Techniques. Intestinal Neoplasms / genetics. Intestinal Neoplasms / metabolism. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17636545.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 95103; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


58. Gerson L, Lin OS: Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol; 2007 Mar;5(3):319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
  • BACKGROUND & AIMS: Esophageal capsule endoscopy (ECE) is a promising new technology for the detection of esophageal pathology.
  • Potential advantages for Barrett's esophagus (BE) screening include ability to return to work as a result of lack of intravenous sedation.
  • For each strategy we determined lifetime costs, life-years gained, numbers of esophageal cancers detected, death rates from esophageal cancer, and procedural deaths.
  • [MeSH-major] Barrett Esophagus / epidemiology. Capsule Endoscopy / economics. Esophagoscopy / economics. Gastroesophageal Reflux / epidemiology. Mass Screening / economics
  • [MeSH-minor] Adenocarcinoma / prevention & control. Aged. Chronic Disease. Cohort Studies. Cost-Benefit Analysis. Esophageal Neoplasms / prevention & control. Humans. Incidence. Male. Middle Aged. Quality-Adjusted Life Years. Risk Factors. Sensitivity and Specificity. Survival Analysis


59. Zhao R, Quaroni L, Casson AG: Fourier transform infrared (FTIR) spectromicroscopic characterization of stem-like cell populations in human esophageal normal and adenocarcinoma cell lines. Analyst; 2010 Jan;135(1):53-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourier transform infrared (FTIR) spectromicroscopic characterization of stem-like cell populations in human esophageal normal and adenocarcinoma cell lines.
  • We have tested an approach to identify putative cancer stem cells that involves measurement of the infrared absorption spectrum of individual cells in an aqueous environment, and their subsequent classification using multivariate data analysis techniques.
  • Two primary esophageal cell lines were characterized: the immortalized normal esophageal epithelial cell line, Het-1A, and the esophageal adenocarcinoma cell line, OE33.
  • [MeSH-major] Adenocarcinoma / chemistry. Esophageal Neoplasms / chemistry. Esophagus / cytology. Neoplastic Stem Cells / chemistry. Spectroscopy, Fourier Transform Infrared / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20024181.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


60. Stewart CJ, Hillery S: Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction. J Clin Pathol; 2007 Nov;60(11):1284-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction.
  • AIMS: To determine the frequency of endocrine cell micronests (ECM) and single endocrine cells (SEC) within the glandular mucosa of the distal oesophagus and oesophagogastric junction (OGJ) following neo-adjuvant therapy for adenocarcinoma.
  • METHODS: The resection specimens from 11 patients with adenocarcinoma of the distal oesophagus or OGJ who had undergone preoperative chemotherapy or chemoradiotherapy (CRT) were reviewed and stained immunohistochemically for cytokeratin and chromogranin.
  • CONCLUSIONS: Endocrine cell pseudo-hyperplasia may be seen within atrophic glandular mucosa following neo-adjuvant therapy of distal oesophageal/OGJ adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Enteroendocrine Cells / pathology. Esophageal Neoplasms / drug therapy. Esophagus / pathology
  • [MeSH-minor] Aged. Atrophy. Combined Modality Therapy. Diagnosis, Differential. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Esophagogastric Junction / radiation effects. Female. Humans. Male. Middle Aged. Mucous Membrane / drug effects. Mucous Membrane / pathology. Mucous Membrane / radiation effects. Neoadjuvant Therapy. Neoplasm, Residual

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] Ann Surg. 2005 Nov;242(5):684-92 [16244542.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] J Clin Pathol. 2006 May;59(5):505-12 [16522747.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1467-74 [16955509.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1039-43 [16467161.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):58-64 [17197919.001]
  • [Cites] Mod Pathol. 2000 May;13(5):475-81 [10824917.001]
  • [Cites] Mod Pathol. 2001 May;14(5):389-96 [11353047.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):841-5 [11684717.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1051-6 [12195189.001]
  • [Cites] Histochem J. 2002 Mar-Apr;34(3-4):173-80 [12495224.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Oct;24(4):631-6; discussion 636-7 [14500086.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):215-23 [15043311.001]
  • [Cites] Histopathology. 1986 Jan;10(1):53-63 [2420694.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):881-90 [2644016.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5A):1907-12 [7847825.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S1-7 [7762735.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1108-20 [10504363.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):397-404 [15706407.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1347-55 [15719440.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):28-35 [16330939.001]
  • (PMID = 17893119.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2095480
  •  go-up   go-down


61. Kalinina T, Bockhorn M, Kaifi JT, Thieltges S, Güngör C, Effenberger KE, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki JR, Yekebas EF: Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer; 2010 Oct 15;127(8):1931-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
  • The purpose of our study was to establish the prognostic significance of IGF-1R in esophageal cancer and to determine the effect of IGF-1R and HER2 targeting with alpha-IR3 and Herceptin antibodies on the proliferation of esophageal cancer cells in vitro.
  • IGF-1R expression and clinicopathological correlations were analyzed with a tissue microarray containing 234 esophageal cancer specimens (133 adenocarcinomas and 101 squamous cell carcinomas).
  • Proliferation changes associated with Herceptin and alpha-IR3 blockage were evaluated with the unique human esophageal cancer cell lines Pt1590 and LN1590.
  • IGF-1R overexpression was detected in 121 (52%) of the 234 esophageal tumors examined.
  • IGF-1R was identified as a variable associated with reduced overall survival for adenocarcinoma (p = 0.05), but not for squamous cell carcinoma.
  • IGF-1R expression can be used as a novel prognostic marker for adenocarcinomas of the esophagus.
  • Cotreatment with IGF-1R and HER2 antibodies might become a valuable and effective treatment option in esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism. Receptor, IGF Type 1 / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Blotting, Western. Cell Proliferation. Esophagus / metabolism. Humans. Immunoenzyme Techniques. Phosphorylation. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Trastuzumab. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104520.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, IGF Type 1; P188ANX8CK / Trastuzumab
  •  go-up   go-down


62. Dent J: Pathogenesis and classification of cancer around the gastroesophageal junction--not so different in Japan. Am J Gastroenterol; 2006 May;101(5):934-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis and classification of cancer around the gastroesophageal junction--not so different in Japan.
  • Japanese patients with early adenocarcinoma of the esophagus have well-preserved gastric acid secretion, consistent with other parts of the world, reinforcing the likely importance of the luminal environment for pathogenesis.
  • [MeSH-major] Esophageal Neoplasms / classification. Esophageal Neoplasms / etiology. Esophagogastric Junction
  • [MeSH-minor] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori. Humans. Japan. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2006 May;101(5):926-33 [16573782.001]
  • (PMID = 16696780.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


63. Anandasabapathy S: Novel Endoscopic Techniques for the Detection of Barrett's Dysplasia. Gastrointest Cancer Res; 2008 Mar;2(2):81-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus is highly prevalent in the US population and is the only known precursor of esophageal adenocarcinoma, one of the most lethal and increasingly common cancers in the developed world.
  • Over the past 4 decades, the incidence of esophageal adenocarcinoma has increased some 300% to 500%.
  • This dramatic trend has sparked tremendous interest in the early diagnosis of Barrett's dysplasia.
  • The diagnosis of dysplasia and early cancer in Barrett's esophagus presents a number of challenges.
  • Used as an adjunct to standard white-light endoscopy, these technologies may enhance the detection of dysplasia and early cancer, thus offering the potential for early diagnosis and improved survival.
  • This article reviews the current status of these novel, optical-based diagnostic technologies and their emerging role in the endoscopic detection of esophageal neoplasia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Lasers Surg Med. 2003;32(1):10-6 [12516065.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] Endoscopy. 2000 Oct;32(10):756-65 [11068834.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • (PMID = 19259299.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2630821
  •  go-up   go-down


64. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV: Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg; 2010 Jul;97(7):1020-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma.
  • BACKGROUND: Obesity is associated with oesophageal adenocarcinoma, but mechanisms linking fat and carcinogenesis remain poorly understood.
  • METHODS: Seventy-five patients with oesophageal adenocarcinoma underwent anthropometric and radiological assessment of obesity.
  • The human oesophageal adenocarcinoma cell line OE33 was used as the calibrator sample.
  • CONCLUSION: Obesity is associated with upregulated ObR and AdipR2 expression in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Esophageal Neoplasms. Esophagogastric Junction. Obesity, Abdominal / complications. Receptors, Adiponectin / metabolism. Receptors, Leptin / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20632267.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOR1 protein, human; 0 / ADIPOR2 protein, human; 0 / Adipokines; 0 / Receptors, Adiponectin; 0 / Receptors, Leptin
  •  go-up   go-down


66. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Selaru FM, Hamilton JP, Yang J, Abraham JM, Mori Y, Meltzer SJ: The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology; 2009 May;136(5):1689-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Barrett's esophagus (BE) is a highly premalignant disease that predisposes to the development of esophageal adenocarcinoma (EAC); however, the involvement of microRNAs (miRs) in BE-EAC carcinogenic progression is not known.
  • METHODS: Esophageal cultured cells (HEEpiC, QhTRT, ChTRT, GihTRT, and OE-33) and esophageal tissues (22 normal epithelia, 24 BE, and 22 EAC) were studied.
  • CONCLUSIONS: The miR-106b-25 polycistron is activated by genomic amplification and is potentially involved in esophageal neoplastic progression and proliferation via suppression of 2 target genes: p21 and Bim.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):372-9 [18449891.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4123-32 [18519671.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Cell. 2004 Jan 23;116(2 Suppl):S93-6, 2 p following S96 [15055593.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):415-7 [15221970.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1996;53:283-319 [8650306.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):384-95 [9430630.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3980-5 [15899785.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2101-3 [16344076.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1090-8 [16247466.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Nat Genet. 2007 Nov;39(11):1384-9 [17965714.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2167-74 [18212054.001]
  • (PMID = 19422085.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA106763-02; United States / NCI NIH HHS / CA / R21 CA106763; United States / NCI NIH HHS / CA / CA084986-09; United States / NCI NIH HHS / CA / CA85069; United States / NCI NIH HHS / CA / CA085069-10; United States / NCI NIH HHS / CA / CA01808; United States / NCI NIH HHS / CA / U01 CA084986-09; United States / NCI NIH HHS / CA / CA085069-08; United States / NCI NIH HHS / CA / U01 CA085069-08; United States / NCI NIH HHS / CA / U01 CA085069-10; United States / NCI NIH HHS / CA / CA001808-05; United States / NCI NIH HHS / CA / CA106763-02; United States / NCI NIH HHS / CA / U01 CA085069; United States / NCI NIH HHS / CA / R01 CA001808-05; United States / NCI NIH HHS / CA / R01 CA001808; United States / NIDDK NIH HHS / DK / T32 DK067872; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Membrane Proteins; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS96324; NLM/ PMC2887605
  •  go-up   go-down


67. Tang LH, Klimstra DS: Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective. Surg Oncol Clin N Am; 2006 Oct;15(4):715-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective.
  • Barrett's esophagus is defined clinically by the presence of endoscopically evident columnar mucosa in the distal esophagus with histopathologic confirmation of the presence of intestinal-type epithelium.
  • The etiology of Barrett's esophagus is understood poorly, but chronic gastroesophageal reflux disease is considered a major contributing factor.
  • Barrett's esophagus is associated with the development of adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030269.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


68. Peters JH: SSAT controversies intramucosal esophageal cancer and high-grade dysplasia: which treatment? Surgical therapy: improved outcomes and piece of mind. J Gastrointest Surg; 2009 Jul;13(7):1179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SSAT controversies intramucosal esophageal cancer and high-grade dysplasia: which treatment? Surgical therapy: improved outcomes and piece of mind.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1589-97 [17909921.001]
  • [Cites] Dis Esophagus. 2008;21(5):377-88 [18564166.001]
  • [Cites] J Gastrointest Surg. 2003 Feb;7(2):164-70; discussion 170-1 [12600440.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):252-7 [15017665.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):439-43 [16437272.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Mayo Clin Proc. 2002 Nov;77(11):1176-81 [12440553.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):294-7 [16333557.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4 [17893503.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2903-9 [18618179.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Dis Esophagus. 2008;21(3):E6-8 [18430096.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • (PMID = 19294473.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


69. Díaz R, Moral P, Fonfría M, de Juan M, Mancheño N, Tormo A: Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy. Clin Transl Oncol; 2010 Apr;12(4):306-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality management of a locally advanced primary oesophageal melanoma with radical surgery and adjuvant chemoimmunoradiotherapy.
  • We present the case of a 46-year-old woman diagnosed with a primary oesophageal melanoma (PEM), who was treated with radical surgery followed by combined chemoimmunotherapy (interferon, carboplatin, dacarbazine and external radiotherapy) and who achieved a complete response after this treatment.
  • The main differential diagnosis is with metastases of skin or ocular malignant melanomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy. Melanoma / pathology. Melanoma / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Esophagectomy. Female. Humans. Hypertension / complications. Immunotherapy / methods. Interferons / administration & dosage. Middle Aged. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Radiotherapy, Adjuvant. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1461-3 [9146346.001]
  • [Cites] Pathol Int. 2008 Jul;58(7):432-5 [18577112.001]
  • [Cites] Onkologie. 2007 Apr;30(4):206-8 [17396044.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):241-4 [11869329.001]
  • [Cites] Surgery. 2006 Jul;140(1):118-9 [16857450.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jan-Mar;69(1):12-4 [16673556.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1675-8 [18834229.001]
  • [Cites] Dis Esophagus. 2002;15(3):244-9 [12444999.001]
  • [Cites] Radiology. 1999 Oct;213(1):97-100 [10540647.001]
  • [Cites] Radiology. 1998 Nov;209(2):455-9 [9807573.001]
  • [Cites] Ann Thorac Surg. 1995 Jul;60(1):217-22 [7598604.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10):1646-51 [15573920.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] Int J Clin Oncol. 2005 Jun;10(3):204-7 [15990972.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):408-10 [17643724.001]
  • [Cites] Melanoma Res. 2007 Aug;17(4):239-42 [17625454.001]
  • [Cites] Dis Esophagus. 2000;13(4):320-3 [11284983.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):525-32 [16474909.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Mar;4(3):171-4 [17339854.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):552-7 [16594751.001]
  • (PMID = 20462842.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 9008-11-1 / Interferons; BG3F62OND5 / Carboplatin
  •  go-up   go-down


70. Badreddine RJ, Prasad GA, Wang KK, Song LM, Buttar NS, Dunagan KT, Lutzke LS, Borkenhagen LS: Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc; 2010 Apr;71(4):697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.
  • BACKGROUND: The incidence and risk factors for recurrence of dysplasia after ablation of Barrett's esophagus (BE) have not been well defined.
  • Indication for ablation was low-grade dysplasia (53 patients, 20%), high-grade dysplasia (152 patients, 58%), and intramucosal cancer (56 patients, 21%).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):403-9 [17325482.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):56-64; quiz 351-2 [18996379.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):659-63 [10840296.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2000 Jul;10(3):409-19 [10899255.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1661-8 [10925965.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):624-30 [10982754.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):554-8 [11323578.001]
  • [Cites] Dig Dis. 2000-2001;18(4):232-9 [11356995.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Mayo Clin Proc. 2002 Nov;77(11):1176-81 [12440553.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):183-8 [12872083.001]
  • [Cites] Biomarkers. 2003 Nov-Dec;8(6):509-21 [15195681.001]
  • [Cites] Gut. 1990 Jan;31(1):4-10 [2318431.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1719-23 [8792687.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):448-55 [9496934.001]
  • [Cites] Gut. 1998 Dec;43(6):747-51 [9824599.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):1-7 [9869715.001]
  • [Cites] Am J Med. 1999 Jun;106(6):642-9 [10378622.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):165-72 [10425407.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1125-31 [15569115.001]
  • [Cites] J Pathol. 2005 Jan;205(1):57-64 [15586364.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):506-14 [15812401.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6650-5 [16425359.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):60-6 [17185080.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1226-33 [17408660.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Gut. 2007 Nov;56(11):1625-34 [17938435.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):38-47 [18076737.001]
  • [Cites] Gut. 2008 Sep;57(9):1200-6 [18460553.001]
  • [CommentIn] Gastrointest Endosc. 2010 Apr;71(4):704-5 [20363412.001]
  • (PMID = 19959164.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK076845-04; United States / NCI NIH HHS / CA / R01 CA097048-05; United States / NCI NIH HHS / CA / R01CA097048; United States / NCI NIH HHS / CA / R01 CA111603; United States / NCI NIH HHS / CA / R03 CA135991; United States / NIDDK NIH HHS / DK / K08 DK076845-05; United States / NIDDK NIH HHS / DK / DK076845-04; United States / NCI NIH HHS / CA / R03CA135991-01; United States / NCI NIH HHS / CA / CA111603-05; United States / NIDDK NIH HHS / DK / K08 DK076845; United States / NCI NIH HHS / CA / CA097048-05; United States / NCI NIH HHS / CA / R01 CA111603-05; United States / NCI NIH HHS / CA / R01 CA097048; United States / NIDDK NIH HHS / DK / DK076845-05; United States / NCI NIH HHS / CA / R01 CA111603-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248054; NLM/ PMC2981349
  •  go-up   go-down


71. Houghton SG, Romero Y, Sarr MG: Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis; 2008 Jan-Feb;4(1):1-4; discussion 4-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Roux-en-Y gastric bypass in obese patients with Barrett's esophagus: attempts to eliminate duodenogastric reflux.
  • BACKGROUND: To assess the effect of Roux-en-Y gastric bypass (RYGB) at a tertiary referral Center of Excellence for bariatric surgery on the length and presence of dysplasia in morbidly obese patients with Barrett's esophagus (BE).
  • Esophageal reflux of gastroduodenal contents (acid, bile) contributes to the development of BE and progression in the dysplasia-carcinoma sequence.
  • Obese patients have a high prevalence of gastroesophageal reflux and might be at an increased risk of developing BE and esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / pathology. Barrett Esophagus / prevention & control. Duodenogastric Reflux / prevention & control. Gastric Bypass. Obesity / complications. Obesity / surgery


72. Iwanski GB, Block A, Keller G, Muench J, Claus S, Fiedler W, Bokemeyer C: Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report. J Med Case Rep; 2008;2:115
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report.
  • INTRODUCTION: Esophageal squamous cell carcinoma (ESCC) is the most common histological subtype of cancer in the upper and middle esophagus and is characterized by a high rate of mortality.
  • The incidence of esophageal cancer varies greatly among regions of the world and occurs at a high frequency in Asia and South America.
  • Cutaneous manifestations of esophageal neoplasia are very rare and are mainly described for esophageal adenocarcinoma (EADC).
  • CONCLUSION: Early biopsies of suspicious skin lesions are important and should be performed in patients with unclear symptoms such as weight loss or dysphagia and especially in patients with a history of cancer, since they can reveal the existence of a distant malignant disease leading to diagnosis and prompt therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2000 Jul;25(7):557-8 [10885705.001]
  • [Cites] Ann Plast Surg. 2001 Feb;46(2):183-4 [11216618.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Ann Dermatol Venereol. 2001 Dec;128(12):1310-5 [11908133.001]
  • [Cites] Can J Gastroenterol. 2005 Nov;19(11):673-6 [16292362.001]
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):19-26 [2298962.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36 [8335743.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • [Cites] Cancer. 1966 Feb;19(2):162-8 [5948332.001]
  • [Cites] Med Clin North Am. 1980 Sep;64(5):885-900 [7432046.001]
  • [Cites] J Am Acad Dermatol. 1995 Aug;33(2 Pt 1):161-82; quiz 183-6 [7622642.001]
  • [Cites] Int J Dermatol. 1988 May;27(4):240-2 [3391711.001]
  • (PMID = 18426583.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2365965
  •  go-up   go-down


73. Odze RD, Lauwers GY: Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy; 2008 Dec;40(12):1008-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy.
  • This review focuses on the histopathological evaluation of endoscopic mucosal resection (EMR) specimens in Barrett's esophagus, and on the histopathological, biological, and molecular properties of postablation Barrett's esophagus.
  • Diagnostic accuracy regarding the grade and stage of neoplasms is improved with the use of EMR, but the value of this technique for treatment is more controversial because of the high prevalence rate of positive margins and the rate of metachronous lesions found elsewhere in the esophagus during follow-up.
  • Ablation techniques, such as argon plasma coagulation, photodynamic therapy, and radiofrequency ablation, are used increasingly for the treatment of Barrett's esophagus and related neoplasms, often in combination with EMR.
  • This is, therefore, concealed to the endoscopist's view and may be allowed to progress to cancer without detection.
  • NSE is histologically similar to normal esophageal squamous epithelium and does not possess the molecular aberrations characteristic of Barrett's esophagus.
  • In contrast, residual nonburied Barrett's esophagus shows persistent pathologic and molecular abnormalities and may progress to cancer upon long term follow-up.
  • The biological potential and rate of progression of nonburied residual Barrett's esophagus following ablation is unclear, but some preliminary studies suggest that the risk may decrease.
  • Buried nondysplastic Barrett's esophagus appears to show decreased biological potential and this may be related to protection from the contents of the lumen by the barrier function of the overlying NSE.
  • On the other hand, anecdotal reports have suggested that buried dysplasia may progress to cancer in some instances.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Cervical Intraepithelial Neoplasia / pathology. Esophageal Neoplasms / pathology. Esophagoscopy. Esophagus / pathology. Esophagus / surgery. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065484.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 63
  •  go-up   go-down


74. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ: Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):727-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma has increased in recent years, and Barrett's esophagus is a recognized risk factor.
  • Increased expression of these enzymes has been found in esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
  • In a population-based case-control study, we examined associations of the COX-2 8473 T>C and iNOS Ser(608) Leu (C>T) polymorphisms with risk of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis.
  • Genomic DNA was extracted from blood samples collected from cases of esophageal adenocarcinoma (n = 210), Barrett's esophagus (n = 212), and reflux esophagitis (n = 230) and normal population controls frequency matched for age and sex (n = 248).
  • The presence of at least one COX-2 8473 C allele was associated with a significantly increased risk of esophageal adenocarcinoma (adjusted odds ratio, 1.58; 95% confidence interval, 1.04-2.40).
  • There was no significant association between this polymorphism and risk of Barrett's esophagus or reflux esophagitis or between the iNOS Ser 608 Leu polymorphism and risk of these esophageal conditions.
  • Our study suggests that the COX-2 8473 C allele is a potential genetic marker for susceptibility to esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Barrett Esophagus / enzymology. Barrett Esophagus / genetics. Cyclooxygenase 2 / genetics. Esophageal Neoplasms / enzymology. Esophageal Neoplasms / genetics. Esophagitis, Peptic / enzymology. Esophagitis, Peptic / genetics. Nitric Oxide Synthase Type II / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349295.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


75. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, vanHam SM, Krishnadath KK: Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol; 2008 Dec;68(6):616-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
  • Immunotherapy for solid cancers, such as oesophageal adenocarcinoma (OAC), is generally hampered by an unfavourable immunological tumour microenvironment.
  • The OAC microenvironment is characterized by a lack of cytokines and factors that normally would enhance anti-cancer responses, such as IFN-gamma and GrB, and by a high expression of several immuno-suppressive factors, such as COX-2, VEGF and IL-8.
  • [MeSH-major] Adenocarcinoma / immunology. Cyclooxygenase 2 / metabolism. Cytokines / metabolism. Esophageal Neoplasms / immunology. Tumor Escape. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055699.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


76. Haghdoost AA, Hosseini H, Chamani G, Zarei MR, Rad M, Hashemipoor M, Zahedi MJ, Darvish-Moghadam S: Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran. Arch Iran Med; 2008 Jul;11(4):364-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran.
  • BACKGROUND: The fall in the incidence of esophageal squamous cell cancer and noncardia gastric cancers in western countries parallels a concomitant rise in the incidence of gastric cardia cancer and distal adenocarcinoma of the esophagus.
  • We aimed to investigate the incidence trend of different gastric and esophageal cancers in Kerman, southeast Iran.
  • METHODS: The information of all newly diagnosed patients with gastric and esophageal cancers were collected actively from all histopathology departments around the Kerman Province during 1991 - 2002 retrospectively.
  • RESULTS: The annual age standardized incidence risks of esophageal and gastric cancers in Kerman were 1.9 and 6.9 per 100,000 populations.
  • In average, the risks of gastric and esophageal squamous cell cancers were more or less constant, while the risk of adenocarcinoma of the esophagus increased around 11% annually.
  • The rising incidence of adenocarcinoma of the esophagus in Kerman parallels its temporal pattern in western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588366.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  •  go-up   go-down


77. Chien CR, Lin CY, Chen CY: Re: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst; 2009 Oct 21;101(20):1428; author reply 1429
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / pathology. European Continental Ancestry Group / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • (PMID = 19724025.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


78. Dughera L, Navino M, Cassolino P, Pellicano R: The diagnosis of gastroesophageal reflux disease. Minerva Gastroenterol Dietol; 2007 Jun;53(2):143-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis of gastroesophageal reflux disease.
  • Gastroesophageal reflux disease (GERD) is known to cause erosive esophagitis, Barrett esophagus and has been linked to the development of adenocarcinoma of the esophagus.
  • Currently, endoscopy is the main clinical tool for visualizing esophageal lesions, but the majority of GERD patients do not have endoscopic visible lesions and other methods are required.
  • Ambulatory esophageal pH monitoring is the gold standard in diagnosing GERD, since it measures distal esophageal acid exposure and demonstrates the relationship between symptoms and acid reflux.
  • [MeSH-major] Gastroesophageal Reflux / diagnosis
  • [MeSH-minor] Algorithms. Esophageal pH Monitoring. Esophagoscopy. Humans. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557042.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Number-of-references] 25
  •  go-up   go-down


79. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, Pearson RB, Thomas RJ, Campbell IG: Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer; 2006 May 15;118(10):2644-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus.
  • We now report that PIK3CA is also mutated in esophageal tumors.
  • Single-strand conformational polymorphism (SSCP) and denaturing high-performance liquid chromatography (DHPLC) were used to screen all 20 exons of PIK3CA in 101 samples from 95 individuals with esophageal cancer and/or Barrett's esophagus.
  • Somatic mutation of PIK3CA was detected in 4 of 35 (11.8%) of esophageal squamous cell carcinomas (SCC) and 3 of 50 (6%) adenocarcinomas.
  • No mutations were detected in any of 17 samples of Barrett's esophagus.
  • No somatic changes were detected in PIK3CB This study extends previous observations in other tumor types by demonstrating the presence of somatic PIK3CA mutations in both SCC and adenocarcinoma of the esophagus, thus implicating the PI3K pathway in the initiation and/or progression of esophageal cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Phosphatidylinositol 3-Kinases / genetics

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16380997.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


80. Konturek PC, Kania J, Burnat G, Hahn EG: NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J Physiol Pharmacol; 2006 Dec;57 Suppl 12:15-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
  • Expression of cyclooxygenase-2 (COX-2) is involved in the chronic inflammation-related development of Barrett's adenocarcinoma and the use of selective COX-2 inhibitors (coxibs) might provide new chemoprevention strategy for Barrett's adenocarcinoma (BA).
  • The role of NO-ASA in the prevention of Barrett's adenocarcinoma (BA) has not been studied so far.
  • 2) to compare the effect of NO-ASA with that of ASA on proliferation rate in Barrett''s adenocarcinoma cell line (OE-33 cells);.
  • The expression of COX-2 was assessed in biopsies obtained from the Barrett's mucosa and normal squamous epithelial esophageal mucosa from 20 BE patients by RT-PCR and Western blot analysis, respectively.
  • These results indicate that this compound may represent a promising chemopreventive agent for Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Aspirin / pharmacology. Cyclooxygenase 2 Inhibitors / pharmacology. Nitric Oxide / metabolism. Nitric Oxide Donors / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Barrett Esophagus / drug therapy. Barrett Esophagus / enzymology. Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Dose-Response Relationship, Drug. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / enzymology. Gene Expression. Humans. In Vitro Techniques

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244951.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitric Oxide Donors; 31C4KY9ESH / Nitric Oxide; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.22.- / Caspase 3; R16CO5Y76E / Aspirin
  •  go-up   go-down


81. Mennigen R, Tuebergen D, Koehler G, Sauerland C, Senninger N, Bruewer M: Endoscopic ultrasound with conventional probe and miniprobe in preoperative staging of esophageal cancer. J Gastrointest Surg; 2008 Feb;12(2):256-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound with conventional probe and miniprobe in preoperative staging of esophageal cancer.
  • BACKGROUND: Using an endoscopic ultrasound (EUS) miniprobe, even highly stenotic esophageal cancers precluding the passage of a conventional probe can be examined without prior dilatation.
  • METHODS: Ninety-seven consecutive patients with esophageal cancer undergoing complete surgical resection were included.
  • CONCLUSIONS: The miniprobe allows adequate EUS staging of stenotic esophageal tumors precluding the passage of a conventional probe.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Endosonography / methods. Esophageal Neoplasms / pathology. Esophagogastric Junction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Constriction, Pathologic. Esophagus / pathology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Gastrointest Endosc. 1995 Jun;41(6):535-9 [7672544.001]
  • [Cites] Br J Surg. 2003 Oct;90(10 ):1220-4 [14515290.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10 ):2813-5 [11051353.001]
  • [Cites] Endoscopy. 2004 Nov;36(11):966-71 [15520913.001]
  • [Cites] Endoscopy. 1993 Feb;25(2):156-61 [8491132.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):997-1002 [11063164.001]
  • [Cites] Gastrointest Endosc. 1992 Jul-Aug;38(4):460-7 [1511822.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jul;5(3):537-47 [7582580.001]
  • [Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]
  • [Cites] Endoscopy. 2002 Jun;34(6):461-3 [12048628.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):16-23 [15990814.001]
  • [Cites] Endoscopy. 1993 Feb;25(2):171-5 [8491135.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10 (4):863-84, x [11641096.001]
  • [Cites] Radiology. 1989 Nov;173(2):411-7 [2678255.001]
  • [Cites] Cancer. 1993 May 15;71(10 ):2910-7 [8490818.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):938-47 [16733107.001]
  • [Cites] Gut. 2002 May;50(5):599-603 [11950802.001]
  • [Cites] Gastrointest Endosc. 1996 Oct;44(4):371-7 [8905352.001]
  • [Cites] Surg Endosc. 2003 Apr;17 (4):615-9 [12582774.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):751-7 [11375583.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):433-9 [15012782.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2167-75 [10070283.001]
  • [Cites] Endoscopy. 1999 May;31(4):291-7 [10376454.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):737-45 [10570330.001]
  • [Cites] Dig Surg. 2000;17 (3):219-24 [10867453.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):95-9 [11756927.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):58-62 [8836718.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23 (20):4483-9 [16002838.001]
  • [Cites] Chirurg. 2003 Mar;74(3):214-21; discussion 222-3 [12647078.001]
  • (PMID = 17823841.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Stolte M: Radiofrequency ablation in Barrett's esophagus. N Engl J Med; 2009 Sep 3;361(10):1021-2; author reply 1022
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / surgery. Catheter Ablation. Esophagus / pathology. Observer Variation
  • [MeSH-minor] Adenocarcinoma / pathology. Humans

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • (PMID = 19731411.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


83. Zhou G, Sun YG, Wang HB, Wang WQ, Wang XW, Fang DC: Acid and bile salt up-regulate BMP4 expression in human esophageal epithelium cells. Scand J Gastroenterol; 2009;44(8):926-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acid and bile salt up-regulate BMP4 expression in human esophageal epithelium cells.
  • OBJECTIVE: Barrett's esophagus (BE) with an intestinal-type epithelium is thought to be a precancerous lesion of adenocarcinoma of the esophagus.
  • The aim of this study was to demonstrate that BMP4 is a molecular mediator that links etiological agents of BE to the phenotypic changes in human esophagus epithelium cells (HEECs).
  • [MeSH-major] Barrett Esophagus / metabolism. Bile Acids and Salts / metabolism. Bone Morphogenetic Protein 4 / biosynthesis. Esophagus / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488929.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bile Acids and Salts; 0 / Bone Morphogenetic Protein 4
  •  go-up   go-down


84. Boone J, Livestro DP, Elias SG, Borel Rinkes IH, van Hillegersberg R: International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus; 2009;22(3):203-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International survey on esophageal cancer: part II staging and neoadjuvant therapy.
  • The purposes of this study were to gain insight into the current worldwide practice of staging modalities and neoadjuvant therapy in esophageal cancer, and to detect intercontinental differences.
  • Surgeons with particular interest in esophageal surgery, including members of the International Society for Diseases of the Esophagus, the European Society of Esophagology - Group d'Etude Européen des Maladies de l'Oesophage, and the OESO, were invited to participate in an online questionnaire.
  • Questions were asked regarding staging modalities, neoadjuvant therapy, and response evaluation applied in esophageal cancer patients.
  • Esophagogastroscopy with biopsy and computed tomography (CT) scanning were routinely performed by 98% of responders for diagnosing and staging esophageal cancer, while endoscopic ultrasound (EUS) and barium esophagography were routinely applied by 58% and 51%, respectively.
  • Of the responders that administer identical neoadjuvant regimens to esophageal adenocarcinoma (AC) and squamous cell carcinoma, 54% favor chemoradiotherapy.
  • In conclusion, currently the most commonly applied diagnostic modalities for staging and restaging esophageal cancer are CT scanning of the chest and abdomen, gastroscopy, barium esophagography and EUS.
  • Intercontinental differences have been detected in the diagnostic modalities applied in esophageal cancer staging and in the administration of neoadjuvant therapy.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19191855.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


85. Gockel I, Sultanov FS, Domeyer M, Trinh TT, Gönner U, Junginger T: [Surgical therapy for esophageal carcinoma: a prospective 20-year analysis]. Zentralbl Chir; 2008 Jun;133(3):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical therapy for esophageal carcinoma: a prospective 20-year analysis].
  • [Transliterated title] Chirurgische Therapie des Osophaguskarzinoms: Eine prospektive 20-Jahres-Analyse.
  • BACKGROUND: The aim of our study was the analysis of long-term developments in the surgical therapy for esophageal carcinoma at our hospital over a period of 20 years with a differentiated view on the two predominant histological tumour types.
  • PATIENTS AND METHODS: Between September 1985 and September 2005, esophageal resections were performed in 470 patients at our clinic on account of a malignant tumour of the esophagus.
  • The abdomino-thoracic resection with abdominal and extended mediastinal lymph node dissection as well as intrathoracic anastomosis was the standard treatment in the case of squamous cell carcinoma, whereas in adenocarcinoma a transhiatal resection with abdominal and dorsal mediastinal lymphadenectomy and cervical esophagogastrostomy was carried out.
  • A proportionally identical amount of transhiatal resections for squamous cell carcinoma was found in both intervals, whereas the transhiatal procedures for adenocarcinoma increased in the last decade (3.6 % in the period between 9 / 1985 and 9 / 1995, as compared with 23.6 % between 10 / 1995 and 9 / 2005) (p < 0.05).
  • While the overall prognosis for squamous cell carcinoma did not significantly differ in the two decades (p = 0.2040), patients with adenocarcinoma were found to have a significantly improved long-term survival (log-rank test: p = 0.0365) in the second decade.
  • The prognosis for adenocarcinoma, therefore, could be improved in the course of time with a 3-year survival rate of finally 40 % (as compared with 17.5 % in the first decade), and a 5-year survival rate of 25 % (as compared with 15 %).
  • CONCLUSION: Surgical therapy for esophageal carcinoma has undergone distinct changes over the past 20 years.
  • Especially with adenocarcinoma of the esophagus, these changes have led to a significantly more favourable long-term prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Diffusion of Innovation. Esophageal Neoplasms / surgery. Thoracotomy / trends
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Diaphragm / surgery. Disease-Free Survival. Esophagus / surgery. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Stomach / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563693.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Fléjou JF, Svrcek M: Barrett's oesophagus--a pathologist's view. Histopathology; 2007 Jan;50(1):3-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus--a pathologist's view.
  • Barrett's oesophagus, a precancerous condition for oesophageal adenocarcinoma, detected on endoscopy and confirmed on histology, shows intestinal metaplasia of the lower oesophagus.
  • The significance of microscopic foci of intestinal metaplasia at the gastro-oesophageal junction, corresponding either to so-called 'ultrashort' segment Barrett's oesophagus, or to carditis with intestinal metaplasia, is still a matter of debate.
  • The surveillance of patients with Barrett's oesophagus is still based on systematic biopsy sampling of Barrett's mucosa on endoscopy, looking for dysplasia.
  • On the other hand, the role of pathologists now extends to the evaluation of new therapeutic modalities of early neoplastic lesions in Barrett's oesophagus, especially endoscopic mucosal resection.
  • [MeSH-major] Barrett Esophagus / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers. Cell Transformation, Neoplastic. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Pathology, Surgical. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Precancerous Conditions / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204017.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 88
  •  go-up   go-down


87. Theisen J, Stein HJ, Feith M, Kauer WK, Dittler HJ, Pirchi D, Siewert JR: Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia. Surg Endosc; 2006 Feb;20(2):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia.
  • BACKGROUND: Barrett's metaplasia is the predominant precursor for the development of esophageal adenocarcinoma.
  • However, sampling error by missing invasive cancer lesions is a common problem.
  • This study aimed to identify preferred locations within a segment of Barrett's mucosa for the development of esophageal adenocarcinoma.
  • METHODS: The study group consisted of 213 patients with histologically proven esophageal adenocarcinoma.
  • Of those, there were 134 cases of early cancer and 79 cases of locally advanced lesions.
  • CONCLUSIONS: The results demonstrate that almost all adenocarcinomas of the esophagus are based on the development of a segment of intestinal metaplasia.
  • The distal margin of Barrett's mucosa seems to be the most vulnerable location for the development of invasive cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Intestines / pathology. Precancerous Conditions / complications. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Surg Endosc. 2002 Apr;16(4):671-3 [11972212.001]
  • [Cites] Gut. 1992 Nov;33(11):1454-8 [1452066.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):507-17 [9309401.001]
  • [Cites] Chest Surg Clin N Am. 1994 May;4(2):217-25 [8049992.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):649-54 [10912484.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):107-11 [8419690.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):66-73 [10228767.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):560-8 [10805842.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):195S-200S [9337287.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):466S-469S [10619510.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Am J Med. 2001 Jul;111(1):33-7 [11448658.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):303-21 [10714623.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16391958.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. van Soest EM, Dieleman JP, Kuipers EJ: The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders. Expert Opin Drug Saf; 2008 Mar;7(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of anticholinergic agents on gastro-oesophageal reflux and related disorders.
  • The most important risk factor of oesophageal adenocarcinoma is gastro-oesophageal reflux disease.
  • Gastro-oesophageal reflux disease is in itself a common disorder, giving bothersome symptoms.
  • In daily clinical practice, anticholinergic drugs are believed to increase the risk of gastro-oesophageal reflux through effects on the lower oesophageal sphincter.
  • In this review we discuss the available literature on the potential association between the use of drugs with anticholinergic properties and the risk of gastro-oesophageal reflux-related disorders.
  • [MeSH-major] Cholinergic Antagonists / adverse effects. Esophagus / drug effects. Gastroesophageal Reflux / chemically induced
  • [MeSH-minor] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324880.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  • [Number-of-references] 58
  •  go-up   go-down


89. Abdel-Latif MM, Windle H, Terres A, Eidhin DN, Kelleher D, Reynolds JV: Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells. J Gastrointest Surg; 2006 Apr;10(4):551-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori extract induces nuclear factor-kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells.
  • Helicobacter pylori infection is recognized as the major cause of gastritis and gastric cancer; however, its role in the development of gastroesophageal reflux disease and Barrett's adenocarcinoma is unclear.
  • The expression of NF-kappaB, AP-1, and COX-2 may be important in inflammation and tumorigenesis in the esophagus.
  • The aim of this study was to examine the effect of live H pylori or H pylori extract (HPE) on these factors in the esophageal epithelial cell lines SKGT-4 and OE33.
  • These data demonstrate that both live H pylori and HPE induce NF-kappaB and AP-1 expression in esophageal epithelial cells.
  • The induction of such transcription factors may play a role in the specific immune response within Barrett's mucosa and may indirectly cause inflammation of the gastric cardia and the distal esophagus.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Esophagus / metabolism. Helicobacter pylori / metabolism. NF-kappa B / biosynthesis. Transcription Factor AP-1 / biosynthesis

  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 1995 Apr;9(2):127-35 [7605852.001]
  • [Cites] Lancet. 1994 Feb 26;343(8896):508-10 [7906759.001]
  • [Cites] J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):825-31 [9648711.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Annu Rev Immunol. 1994;12:141-79 [8011280.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):915-9 [8088767.001]
  • [Cites] Adv Immunol. 1995;58:1-27 [7741027.001]
  • [Cites] Digestion. 1996 Nov-Dec;57(6):433-45 [8913706.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1023-9 [9298878.001]
  • [Cites] Dig Dis Sci. 1994 Apr;39(4):770-5 [7512016.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1983-91 [9394739.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1524-33 [8942731.001]
  • [Cites] Scand J Gastroenterol. 1999 Jul;34(7):658-62 [10466875.001]
  • [Cites] Dis Esophagus. 1997 Jul;10(3):196-200 [9280079.001]
  • [Cites] Gut. 2001 Sep;49(3):364-71 [11511558.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10 ):2277-84 [11680608.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):491-500 [15024310.001]
  • [Cites] Scand J Gastroenterol. 1994 May;29(5):425-9 [8036458.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):68-76 [12559187.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):15-24 [9207257.001]
  • [Cites] Gut. 1997 Sep;41(3):277-80 [9378377.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3175-80 [10566710.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):187-9 [2568521.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40 [2494664.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] J Appl Physiol. 1975 Sep;39(3):479-81 [1176415.001]
  • [Cites] Dig Dis Sci. 1995 Jun;40(6):1292-6 [7781450.001]
  • [Cites] Gut. 1998 Jul;43 Suppl 1:S6-9 [9764031.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1099-109 [9322504.001]
  • (PMID = 16627221.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antioxidants; 0 / Cell Extracts; 0 / Cyclooxygenase 2 Inhibitors; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Pyridines; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; OU13V1EYWQ / SB 203580; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


90. Ehsani MJ, Maleki I, Mohammadzadeh F, Mashayekh A: Epidemiology of gastroesophageal reflux disease in Tehran, Iran. J Gastroenterol Hepatol; 2007 Sep;22(9):1419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Gastroesophageal reflux disease is a serious and unresolved problem in Western countries, and its increasing prevalence correlates with an increasing prevalence of adenocarcinoma of distal esophagus.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Reflux in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716346.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


91. Kitabatake S, Niwa Y, Goto H: [The clinical strategy for the Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical strategy for the Barrett's esophagus].
  • The treatment of Barrett's esophagus is controversial.
  • Current treatments include endoscopic therapy, surgical procedures, gastric acid-suppressive therapy with proton pump inhibitors (PPIs), and cancer chemoprevention such as nonsteroidal anti-inflammatory drugs.
  • Antireflux surgery and PPIs therapy are potential options for the treatment of gastroesophageal reflux symptoms in patients with Barrett's esophagus.
  • Although chemoprevention therapy may reduce cancer risk in Barrett's esophagus, no randomized controlled trials that prove its efficacy have been reported.
  • [MeSH-major] Barrett Esophagus / therapy
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / therapeutic use. Digestive System Surgical Procedures / methods. Enzyme Inhibitors / therapeutic use. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Esophagitis, Peptic / therapy. Esophagoscopy. Esophagus / surgery. Humans. Lansoprazole. Membrane Proteins. Nitrobenzenes / therapeutic use. Omeprazole / analogs & derivatives. Omeprazole / therapeutic use. Prostaglandin-Endoperoxide Synthases / physiology. Proton Pump Inhibitors. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101235.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Membrane Proteins; 0 / Nitrobenzenes; 0 / Proton Pump Inhibitors; 0 / Sulfonamides; 0K5C5T2QPG / Lansoprazole; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; KG60484QX9 / Omeprazole
  • [Number-of-references] 15
  •  go-up   go-down


92. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A: A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer; 2008 Feb;44(3):465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
  • We examined the association between BMI and EADC, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in a cohort of approximately 500,000 people in the United States (US).
  • We found that compared to people with a BMI of 18.5-25kg/m2, a BMI > or = 35 was associated with significantly increased risk of EADC, HR (95% CI)=2.27 (1.44-3.59) and gastric cardia adenocarcinoma 2.46 (1.60-3.80), but not gastric non-cardia adenocarcinoma 0.84 (0.50-1.42).
  • [MeSH-major] Adenocarcinoma / etiology. Attitude to Health. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):319-23 [3856045.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18221867.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS42480; NLM/ PMC2350215
  •  go-up   go-down


93. Kadioglu E, Sardas S, Ergun M, Unal S, Karakaya AE: The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus. Toxicol Ind Health; 2010 Mar;26(2):67-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus.
  • Determination of the genetic alterations, which play a role in the etiology of Barrett's esophagus (BE), could help identify high-risk individuals for esophageal adenocarcinoma (EA).
  • [MeSH-major] Barrett Esophagus / enzymology. Barrett Esophagus / genetics. DNA Damage / physiology. DNA Glycosylases / genetics. Glutathione Transferase / genetics. Superoxide Dismutase / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20056743.001).
  • [ISSN] 1477-0393
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; BBX060AN9V / Hydrogen Peroxide; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; GAN16C9B8O / Glutathione
  •  go-up   go-down


94. Gillen S, Feith M, Gertler R, Langer R, Massmann J, Sarbia M, Friess H: Testicular metastasis from adenocarcinoma of the esophagus. Ann Thorac Surg; 2009 Mar;87(3):957-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular metastasis from adenocarcinoma of the esophagus.
  • We report the case of a 61-year-old patient, operated on for adenocarcinoma of the esophagus in 2002, who presented in 2007 with a hydrocele and palpable mass of the right testis.
  • Histopathology revealed a testicular and epididymidal metastasis from the esophageal adenocarcinoma.
  • No case of testicular metastasis from esophageal cancer, including Barrett's carcinoma has been reported.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231438.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Bhurgri Y, Nazir K, Shaheen Y, Usman A, Faridi N, Bhurgri H, Malik J, Bashir I, Bhurgri A, Hasan SH, Kayani N, Zaidi SH: Patho-epidemiology of cancer corpus uteri in Karachi South '1995-1997'. Asian Pac J Cancer Prev; 2007 Oct-Dec;8(4):489-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patho-epidemiology of cancer corpus uteri in Karachi South '1995-1997'.
  • AIM: To provide demographics and pathology of cancer of the uterine corpus in Karachi.
  • METHODOLOGY: Data for 66 incident cases of cancer corpus uteri, ICD-10 category C54-5 registered at the Karachi Cancer Registry, for Karachi South, during a 3 year period, 1st January, 1995 to 31st December 1997 were reviewed.
  • RESULTS: Cancer uterine corpus (1995-97) was the sixth most common malignancy, following breast, oral cavity, ovary, esophagus and cervix.
  • CONCLUSION: The incidence of cancer corpus uteri in Karachi South reflects a moderate risk population, predominantly middle aged with a higher socio-economic status.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Middle Aged. Pakistan / epidemiology. Risk Factors. Sarcoma / epidemiology. Sarcoma / pathology. Time Factors. Young Adult


96. Curvers WL, Peters FP, Elzer B, Schaap AJ, Baak LC, van Oijen A, Mallant-Hent RM, Ten Kate F, Krishnadath KK, Bergman JJ: Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol; 2008 Jul;20(7):601-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In short Barrett's oesophagus, the adherence to current standard biopsy protocols is acceptable, but in longer segments (with a higher risk for neoplastic progression) this is clearly insufficient.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Population Surveillance / methods. Precancerous Conditions / pathology. Quality of Health Care

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679060.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS: A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest; 2006 Jun-Jul;24(4):346-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.
  • Platinum-based combination chemotherapy regimens increasingly are accepted as a first-line treatment option for patients with advanced gastroesophageal adenocarcinoma.
  • Vinorelbine is both well tolerated and active in patients with advanced breast, lung cancer, and squamous cell carcinoma of the esophagus, but has not previously been evaluated as a single agent in gastroesophageal adenocarcinoma.
  • Twenty-nine patients with previously treated or untreated metastatic gastroesophageal adenocarcinoma were treated with weekly vinorelbine, administered at a dose of 25 mg/m2, and were followed for evidence of radiologic response, toxicity, and survival.
  • We conclude that vinorelbine has minimal toxicity but only minor antitumor activity in patients with advanced gastroesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / adverse effects. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777685.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 093401; United States / NHLBI NIH HHS / HL / K30 HL04095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


98. Buskens CJ, Ten Kate FJ, Obertop H, Izbicki JR, van Lanschot JJ: Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia. Dis Esophagus; 2008;21(6):488-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia.
  • SUMMARY: Lymphatic dissemination is the most important prognostic factor in patients with esophageal carcinoma.
  • The aim of the present study was to identify the incidence of potentially relevant micrometastatic disease in patients with histologically node-negative esophageal adenocarcinoma and to analyze the sensitivity and specificity of three different immunohistochemical assays.
  • From a consecutive series of 79 patients who underwent a transthoracic resection with extended 2-field lymphadenectomy, all 20 patients with pN0 esophageal adenocarcinoma were included in this study.
  • For the detection of clinically relevant micrometastatic disease in patients operated upon for adenocarcinoma of the distal esophagus or gastric cardia, Ber-EP4 is the antibody of first choice because of its high sensitivity and specificity.
  • Therefore, this technique has the potential to refine the staging system for esophageal cancer and to help identify patients who will not be cured by surgery alone.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840133.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


99. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, Ten Kate FJ, Reitsma PH, van Kampen AH, Zwinderman AH, Baas F, van Lanschot JJ: Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol; 2008 Dec;15(12):3459-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus.
  • INTRODUCTION: The presence of lymphatic dissemination is an important predictor of survival in esophageal adenocarcinoma (EA).
  • Whole-genome oligonucleotide microarrays were used to evaluate the genetic signature of 77 esophageal cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825457.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


100. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, Nicolson M, Harper P, Seymour M, Hickish T: The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol; 2009 May;20(5):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
  • BACKGROUND: It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma].
  • This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy.
  • RESULTS: Of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n = 485), OGJ (n = 457) and gastric (n = 833) origins.
  • The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P = 0.68).
  • RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P = 0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis).
  • Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P = 0.85 and 0.62 compared with gastric).
  • CONCLUSIONS: In our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma.
  • Future RCTs should not exclude oesophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164454.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement